{"chunk_type":"transcript_chunk","text":"# DIP\nINTERNAL MEDICINE\n- Ep 29 (IM 1 Video)\n- Ep 30 (IM 2 Video)\n- Ep 31 (IM 3 Video)\n- Ep 32 (IM 4 Video)\n- Ep 41 (Antibiotic Guide)\n- Ep 100 (Clutch Micro)\n- Ep 104 (ACLS, Arrhythmias)\n- Ep 129 (Targeted Pulm)\n- Ep 244 (Valvular Disorders)\n- Ep 251 (Thyroid)\n- Ep 253 (Starling Forces)\n- Ep 293-NBME GI Series 1\n- Ep 294-NBME GI Series 2\n- Ep 295-NBME GI Series 3\n- Ep 298-NBME GI Series 4\n- Ep 318-NBME GI Series 5\n- Ep 319-NBME GI Series 6\n- Ep321-Clutch Metabolic Acidosis\n- Ep 331-Clutch Lung Cancer Podcast\n- Ep 332-Clutch Pleural Abnormalities/Effusions Podcast\n- Ep 333-Pressors/Inotropes for Step 2CK/3\n- Ep 339-The HY Pulmonary Embolism Podcast\n- Ep 353-The Clutch Pulmonary HTN Podcast\n- Ep 356-The Clutch UTI Podcast\n- Ep 360-The Clutch Secondary HTN Podcast\n- Ep 367-The Clutch Amyloidosis Podcast\n- Ep 376-Thyroid Cancer\n- Ep 384-IBDs and the USMLEs\n- Ep 404-The Floridly HY CXR Podcast\n- Ep 437-Infectious Populations (IVDUs)\n- Ep 439-Anion Gap Metabolic Acidosis 1\n- Ep 445-Clutch MI Complications\n- Ep 460-Floridly HY Antibiotic Review Part 1\n- Ep 461-Floridly HY Antibiotic Review Part 2\n- Ep 470-Numerical Acid Base Problems and the USMLEs\n- Ep 477-Clutch Acute Coronary Syndromes\n- Ep 492-The Clutch Septic Joint Podcast\n- Ep 496-Aortic regurgitation and some USMLE integrations\n- Ep 503-LFTs and The USMLEs\n- Ep 507-Clutch Sickle Cell Disease Part 1\n- Ep 508-Clutch Sickle Cell Disease Part 2\n- Ep 514-A Framework For Understanding Endocrine Testing\n- Ep 515-Ventilator Physiology Part 2\n- Ep 524-The Clutch Osteomyelitis Podcast\n- Ep 539-50 HY Corticosteroid facts to know for Step 1-3\n- Ep 550-The Iron Story and The USMLEs Part 1\n- Ep 552-The Iron Story and The USMLEs Part 2\n- Ep 554-What is this antibiotic used for?\n- Ep 570-The Clutch Skin and Soft Tissue Infections Podcast\n- Ep 586-Quick and Dirty Microbiology Associations\n- Ep 600-Intuition and Integrations With Select Equations\n- Ep 602-Endocrine Thinking (Stimulation and Suppression Te...)\n- Ep 605-The Extremely HY RBC Podcast\n- Ep 623-Last Minute Microbiology Review for Step 2 and 3\n- Ep 625-The 5 USMLE Gaps\nSURGERY\n- Ep 24\n- Ep 180 (Heme)\n- Ep 221 (Trauma)\n- Ep 377-GI Bleeds\n- Ep 304 (Trauma 2)\n- Ep 610-Imaging and The USMLEs (Part 1)\nOBGYN\n- Ep 22\n- Ep 118(Breast)\n- Ep239 (Risk factors)\n- Ep278(Amenorrhea)\n- Ep309(Breast Cancer)\n- Ep 338-Fetal Heart Rate Tracings\n- Ep 350-The Clutch Teratogen Podcast\n- Ep 357-Disorders of Sexual Differentiation\n- Ep 373-Progestin and Estrogen Challenge Tests\n- Ep 459-The Clutch STI Podcast\n- Ep 467-The Clutch Cervical Cancer Podcast\n- Ep 493-The Superclutch Infertility Podcast\n- Ep 531-The HY Contraceptive Podcast\nPSYCH\n- Ep 23\n- Ep 164 (Toxicology)\n- Ep 349-Psych Pharm\n- Ep 451-Serotonin Syndrome (with integrations)\n- Ep 452-NMS and Malignant Hyperthermia (vs serotonin syndr...)\n- Ep 453-Psychiatry Timelines\nPEDS\n- Ep 17\n- Ep 21\n- Ep 223 (Newborns)\n- Ep317(Breastfeeding, newborn jaundice)\n- Ep 326-Peds Cardio and Hemodynamic Changes\n- Ep 421-Pulmonary Pathophysiology Series 11\n- Ep 507-Clutch Sickle Cell Disease Part 1\n- Ep 508-Clutch Sickle Cell Disease Part 2\nNEURO\n- Ep 19 (Series 1)\n- Ep 45 (Series 2)\n- Ep 46 (Series 3)\n- Ep 47 (Series 4)\n- Ep 48 (Series 5)\n- Ep 49 (Series 6)\n- Ep 58 (Series 7)\n- Ep 59 (Series 8)\n- Ep 361-The Eye 1\n- Ep 365-The Eye 2\n- Ep 371-The Spinal Cord\n- Ep 372-Clutch Headache Podcast\n- Ep 374-Spinal Cord Lesions\n- Ep 435-Neuromuscular Junction Disorders\n- Ep 457-Horner's Syndrome\n- Ep 506-Weird but HY Spinal Cord Disorders\n- Ep 516-The Floridly HY Brain Tumor Podcast\n- Ep 543-Facial Muscle Weakness\n- Ep 546-Super HY USMLE Neurology Integrations\n- Ep 599-The Clutch Dementia Podcast\nRAPID REVIEW SERIES\n- Ep 94 (Series 1, Peds)\n- Ep 95 (Series 2, Peds)\n- Ep 119 (Series 3, IM)\n- Ep 120 (Series 4, IM/Peds)\n- Ep 121 (Series 5, IM/Peds)\n- Ep 125 (Series 6, IM)\n- Ep 126 (Series 7, IM)\n- Ep 127 (Series 8, OB)\n- Ep 128 (Series 9, IM)\n- Ep 130 (Series 10, Peds)\n- Ep 131 (Series 11, All)\n- Ep 134 (Series 12, IM)\n- Ep 141 (Series 13, IM)\n- Ep 145 (Series 14, Surgery)\n- Ep 153 (Series15, Surgery)\n- Ep 156 (Series 16, OB)\n- Ep 158(Series 17, Surgery)\n- Ep 159 (Series 18, IM)\n- Ep 163 (Series 19, Surgery)\n- Ep 166 (Series 20, Psych)\n- Ep 167 (Series 21, Cardio)\n- Ep 174 (Series 22, IM)\n- Ep 175 (Series 23, Psych)\n- Ep 177 (Series 24, OBGYN)\n- Ep 187 (Series 25)\n- Ep 189 (Series 26)\n- Ep 195 (Series 27)\n- Ep 196 (Series 28)\n- Ep 199 (Series 29)\n- Ep 202 (Series 30)\n- Ep 210 (Series 31)\n- Ep 211 (Series 32, Neuro)\n- Ep 219 (Series 33)\n- Ep 220 (Series 34)\n- Ep 225 (Series 35)\n- Ep 227 (Series 36-HY OB)\n- Ep 238 (Series 37)\n- Ep 240 (Series 38, OB/Ortho)\n- Ep 245-Series 39\n- Ep 247-Series 40\n- Ep 256-Series 41\n- Ep 258-Series 42\n- Ep 270-Series 43\n- Ep 272-Series 44\n- Ep 274-Series 45\n- Ep 282-Series 46\n- Ep 283-Series 47\n- Ep 284-Series 48 (Bone)\n- Ep 285-Series 49\n- Ep 290-Series 50\n- Ep 291-Series 51\n- Ep 297-Series 52\n- Ep 299-Series 53\n- Ep 306-Series 54\n- Ep 307-Series 55\n- Ep 312-Series 56\n- Ep 314-Series 57\n- Ep 316-Series 58\n- Ep 320-Series 59\n- Ep 324-Series 60\n- Ep 330-Series 61\n- Ep 334-Series 62\n- Ep 335-Series 63\n- Ep 336-Series 64\n- Ep 344-Series 65\n- Ep 351-Series 66\n- Ep 355-Series 67\n- Ep 358-Series 68\n- Ep 366-Series 69\n- Ep 369-Series 70\n- Ep 370-Series 71\n- Ep 380-Series 72\n- Ep 382-Series 73\n- Ep 390-Series 74\n- Ep 391-Series 75\n- Ep 394-Series 76\n- Ep 396-Series 77\n- Ep 401-Series 78\n- Ep 403-Series 79\n- Ep 405-Series 80\n- Ep 408-Series 81\n- Ep 412-Series 82\n- Ep 413-Series 83\n- Ep 415-Series 84\n- Ep 420-Series 85\n- Ep 423-Series 86\n- Ep 426-Series 87\n- Ep 427-Series 88\n- Ep 431-Series 89\n- Ep 434-Series 90\n- Ep 438-Series 91\n- Ep 442-Series 92\n- Ep 449-Series 93\n- Ep 454-Series 94\n- Ep 456-Series 95\n- Ep 462-Series 96\n- Ep 466-Series 97\n- Ep 468-Series 98\n- Ep 473-Series 99\n- Ep 476-Series 100\n- Ep 490-Series 101\n- Ep 483-Series 102\n- Ep 486-Series 103\nBIOSTATS AND ETHICS\n- Ep 123 (Ethics 1)\n- Ep 132 (Social Sciences)\n- Ep 143 (Biostats)\n- Ep 197 (Bias in Biostats)\n- Ep 337-Drug Ads\n- Ep 363-Confounding\n- Ep 364-Effect modification\nSPECIAL TOPICS/RISK FACTORS\n- Ep 36 (Ophtho)\n- Ep 37 (Risk Factors 1)\n- Ep 41 (Antibiotic Guide)\n- Ep 65 (Ventilators)\n- Ep 97 (Risk Factors, Important)\n- Ep 100 (Clutch Micro)\n- Ep 102 (Clutch Cancer)\n- Ep 111 (Clutch Pharm 1)\n- Ep 112 (Clutch Pharm 2)\n- Ep 135 (Clutch Electrolyte)\n- Ep 137 (Next Best Step 1)\n- Ep 138 (Clutch Genetic Dzs)\n- Ep 161 (Clutch Autoantibody)\n- Ep 164 (Clutch Toxicology)\n- Ep 169 (Nephrotic/Nephritic)\n- Ep 173 (Clutch Immunodeficiency)\n- Ep 184 (NBME Weird, Must Know!)\n- Ep 197 (Bias in Biostatistics)\n- Ep 198 (Hypertensive Integrations)\n- Ep 203 (Leukemias/Lymphomas)\n- Ep 204 (USMLE Military)\n- Ep 207 (Geriatrics 1)\n- Ep 208 (Transfusion Reactions)\n- Ep 215 (NBME Acetylcholine)\n- Ep 216 (Step 1 P/F)\n- Ep 221 (HY Trauma)\n- Ep 224 (Genetic Diseases 2, Chromosomes)\n- Ep 226 (The NBME and Iron Labs)\n- Ep 231 (USMLE Military 2)\n- Ep 232 (Vasculitis)\n- Ep 233 (Shock)\n- Ep 234-CLEAN SP 3 (medication/transition errors)\n- Ep 235-Admitting Patients Efficiently\n- Ep 239-OBGYN Risk Factors\n- Ep 242-USMLE Dermatology 1\n- Ep 243-The USMLEs and Water Sol. Vitamins\n- Ep 244-The NBME and Valvular Disorders\n- Ep 246-USMLE Dermatology 2\n- Ep 248-New Free 120 Q1-10 (2020)\n- Ep 249-Oxygen Content\n- Ep 250-HY Vaccine Podcast\n- Ep 251-Thyroid and The NBMEs\n- Ep 252 (Post exposure prophylaxis)\n- Ep 253 (Starling Forces and The NBMEs)\n- Ep 255-Key Drugs for Step 2CK/3\n- Ep 257-Clutch Bilirubin\n- Ep 261-USMLE Dermatology 3\n- Ep 263-Clutch CNS Infections\n- Ep 264-Clutch Heart Failure\n- Ep 265-Male Reproductive Pathologies\n- Ep 267-Normal Changes with Aging\n- Ep 269-NBME Ortho: Bone Tumors\n- Ep 273-The NBME and High Output HF\n- Ep 278- The NBME and Amenorrhea\n- Ep 279-The NBME and Prostaglandins\n- Ep 281-Fat Soluble Vitamins and the USMLEs\n- Ep 282-Risk Factors 5/Rapid Review Series 46\n- Ep 283-Risk Factors 6/Rapid Review Series 47\n- Ep 286-The Ultra HY ARDS Podcast\n- Ep 287-The Ultra HY Urinalysis Podcast\n- Ep 288-Stress Tests/TEEs on the USMLE\n- Ep 289-Alcoholism and the USMLEs\n- Ep 292-NBME Endocarditis and Myocarditis\n- Ep 300-Coronavirus/COVID-19\n- Ep 301-Diabetes and The USMLEs Part 1\n- Ep 302-Diabetes and The USMLEs Part 2\n- Ep 303-Diabetes and The USMLEs Part 3\n- Ep 304-The Floridly HY Trauma Podcast 2\n- Ep 305-Upper Limb Rapid Review 1\n- Ep 308-The Floridly HY NBME Cortisol Podcast\n- Ep 309-The Clutch Breast Cancer Podcast\n- Ep 310-The Floridly HY Knee Exam/Pathologies Podcast\n- Ep 311-Clutch CSF/Brain Imaging Podcast\n- Ep 313-The Floridly HY Hyperkalemia Podcast\n- Ep 315-The Clutch Circle of Willis Podcast\n- Ep 321-Clutch Metabolic Acidosis\n- Ep 323-Immunocompromised/Transplant Patients\n- Ep 328-Vitamin B12 Deficiency and the USMLEs\n- Ep 329-Thriving Through Transitions (Wellness)\n- Ep 331-The Clutch Lung Cancer Podcast\n- Ep 332-The Clutch Pleural Anomalies/Effusions Podcast\n- Ep 339-The HY Pulmonary Embolism Podcast\n- Ep 340-Genetic Syndromes and Cancers for the USMLEs\n- Ep 343-Paraneoplastic Syndromes and The USMLEs\n- Ep 346-Cardiovascular Pharm for Step 2CK/3 Part 1\n- Ep 347-Cardiovascular Pharm for Step 2CK/3 Part 2\n- Ep 348-The Clutch Hypercalcemia Podcast\n- Ep 349-Clutch Psych Pharm Review for the shelf exam, Step...\n- Ep 352-The Clutch Fungi Podcast for Step 2CK/3\n- Ep 357-Disorders of Sexual Differentiation\n- Ep 372-The Clutch Headache Podcast\n- Ep 375-Hardy Weinberg Made Easy\n- Ep 377-The Clutch GI Bleed Podcast\n- Ep 379-A Series of HY Elderly Vignettes for Step 1-3\n- Ep 381-Some HY Pharmacology Vignettes for Step 2CK/3\n- Ep 383-The Clutch Smoking Podcast\n- Ep 385-Anesthetic Complications and The USMLEs\n- Ep 387-Adverse Drug Reactions for Step 2CK/3\n- Ep 388-Clutch Hypocalcemia Podcast\n- Ep 392-Pulmonary Pathophysiology Series 1\n- Ep 393-Pulmonary Pathophysiology Series 2\n- Ep 395-The Clutch Diabetes Management Podcast\n- Ep 397-Pulmonary Pathophysiology Series 3\nEMED","subject":"DIP 2ec46f2986ee8056a3cedf522b3f7170","page_title":"DIP 2ec46f2986ee8056a3cedf522b3f7170","episode":"DIP 2ec46f2986ee8056a3cedf522b3f7170","section_path":["DIP 2ec46f2986ee8056a3cedf522b3f7170"],"source_doc_id":"DIP 2ec46f2986ee8056a3cedf522b3f7170","source_page":null,"source_anchor":"DIP 2ec46f2986ee8056a3cedf522b3f7170-1","focus_area":"DIP 2ec46f2986ee8056a3cedf522b3f7170","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"- Ep 181 (EMED1)\n- Ep 182 (EMED2)\n- Ep 183 (EMED3)\n- Ep221(Trauma)\n- Ep 304-Trauma\n- Ep 399-The 3 Confusing Poisonings\n- Ep 571-Quick and Dirty Emergency Medicine\n- Ep 572-Quick and Dirty Emergency Medicine 2\n- Ep 574-Quick and Dirty Emergency Medicine 3\n- Ep 578-Quick and Dirty Emergency Medicine 4\nFAMILY MEDICINE\n- Ep 206 (Series 1)\n- Ep 209 (Series 2) Psych\n- Ep 212 (Series 3) GI\n- Ep 213 (Series 4) GI\n- Ep 214 (Series 5) GI\n- Ep 217 (Series 6) Pulm\nNOVEMBER 2020 CHANGES\n- Ep 228-Palliative Care 1\n- Ep 230-Quality and Safety\n- Ep 234-Medication/Care Transition Errors\n- Ep 268-Palliative Care 2\n- Ep 275-Diagnostic Errors\n- Ep 123-Ethics\n- Ep 276-Professionalism/Ethics\n- Ep 277-Infection Control/Prevention\n- Ep 325-Extremely HY Screening Guidelines\n- Ep 530-Cognitive Errors and The USMLEs\n- Ep 613-Perioperative Medicine\nOTHERS\n- Ep 236-2CK 1 day class.\n- Ep 266-ERAS Advice\n- Ep 296-Match Day 2021(Advice and Thoughts)\n- Ep 327-26 Rules for ERAS and M4 Year\n- Ep 342-Common ERAS App Mistakes\n- Ep 354-How to preround efficiently\nICU Series\n- Ep 416-Foundation (Series 1)\n- Ep 429-Crystalloid Solutions (Series 2)\nPHARMACOLOGY FOR STEP 2/3\n- Episode 484-Series 1 (Pain Control)\nFREE 120 SERIES (Step 2CK)\n- Episode 518-2024 Step 2CK Part 1\n- Episode 519-2024 Step 2CK Part 2\n- Episode 520-2024 Step 2CK Part 3\n- Episode 521-2024 Step 2CK Part 4\n- Episode 522-2024 Step 2CK Part 5\n- Episode 523-2024 Step 2CK Part 6\n- Episode 525-2024 Step 2CK Part 7\n- Episode 526-2024 Step 2CK Part 8\n- Episode 528-2024 Step 2CK Part 9\n- Episode 529-2024 Step 2CK Part 10\n- Episode 533-2024 Step 2CK Part 11\n- Episode 535-2024 Step 2CK Part 12\n- Episode 537-2024 Step 2CK Part 13\n- Episode 538-2024 Step 2CK Part 14 (final)\nFREE 137 SERIES (Step 3)\n- Episode 548-2024 Step 3 Part 1 (Q1-10)\n- Episode 549-2024 Step 3 Part 2 (Q11-20)\n- Episode 555-2024 Step 3 Part 3 (Q21-30)\n- Episode 556-2024 Step 3 Part 4 (Q31-40)\n- Episode 557-2024 Step 3 Part 5 (Q41-50)\n- Episode 558-2024 Step 3 Part 6a (Q51-54)\n- Episode 559-2024 Step 3 Part 6b (Q55-60)\n- Episode 560-2024 Step 3 Part 7 (Q61-70)\n- Episode 561-2024 Step 3 Part 8 (Q71-80)\n- Episode 562-2024 Step 3 Part 9 (Q81-91)\n- Episode 563-2024 Step 3 Part 10 (Q92-100)\n- Episode 564-2024 Step 3 Part 11a (Q101-104)\n- Episode 565-2024 Step 3 Part 11b (Q105-110)\n- Episode 566-2024 Step 3 Part 12 (Q111-120)\n- Episode 567-2024 Step 3 Part 13 (Q121-130)\n- Episode 568-2024 Step 3 Part 14 (Q131-137)","subject":"DIP 2ec46f2986ee8056a3cedf522b3f7170","page_title":"DIP 2ec46f2986ee8056a3cedf522b3f7170","episode":"DIP 2ec46f2986ee8056a3cedf522b3f7170","section_path":["DIP 2ec46f2986ee8056a3cedf522b3f7170"],"source_doc_id":"DIP 2ec46f2986ee8056a3cedf522b3f7170","source_page":null,"source_anchor":"DIP 2ec46f2986ee8056a3cedf522b3f7170-21","focus_area":"DIP 2ec46f2986ee8056a3cedf522b3f7170","tags":["usmle-step2","core"]}
{"chunk_type":"transcript_chunk","text":"# UTI ì¹˜ë£Œ\n![image.png](UTI%20%EC%B9%98%EB%A3%8C/image.png)\n![image.png](UTI%20%EC%B9%98%EB%A3%8C/image%201.png)\n![image.png](UTI%20%EC%B9%98%EB%A3%8C/image%202.png)\n## 3. ğŸ’Š Master Rx Table (ì¹˜ë£Œ ì¡±ë³´)\n| ì§„ë‹¨ëª… | ëŒ€ìƒ (Population) | 1ì°¨ ì¹˜ë£Œì œ (Regimen) | ê¸°ê°„ | Exam Tip |\n| --- | --- | --- | --- | --- |\n| **ASB** | ì¼ë°˜ì¸/ë…¸ì¸/ë„ë‡¨ê´€ | **ì¹˜ë£Œ ì•ˆ í•¨ (X)** | - | ì¹˜ë£Œí•˜ë©´ ë‚´ì„±ê· ë§Œ í‚¤ì›€. |\n| **ASB** | **ì„ì‚°ë¶€** / ì‹œìˆ  ì „ | Nitro, Cepha | 4-7ì¼ | ì¡°ì‚° ì˜ˆë°© ìœ„í•´ í•„ìˆ˜ ì¹˜ë£Œ. |\n|  |  |  |  |  |\n| **Cystitis** | **ë‹¨ìˆœ (ê±´ê°•å¥³)** | Nitro, Fosfo, TMP | 3-5ì¼ | ì§§ê³  êµµê²Œ. Culture ë¶ˆí•„ìš”. |\n| **Cystitis** | **ë³µì¡ (ë‚¨ì ë“±)** | FQ (Cipro) | 7ì¼ | Culture í•„ìˆ˜. ì „ë¦½ì„  í™•ì¸. |\n| **Cystitis** | **ì„ì‚°ë¶€** | Cephalexin, ì•„ëª¨í´ë¼ | 7ì¼ | 3ì¼ ìš”ë²•ì€ ì¬ë°œ í”í•¨. ê¸¸ê²Œ. |\n|  |  |  |  |  |\n| **Pyelo** | **ë‹¨ìˆœ (ê±´ê°•å¥³)** | **PO** Cipro | 7ì¼ | ì™¸ë˜ ì¹˜ë£Œ ê°€ëŠ¥ (ì§‘ì— ë³´ëƒ„). |\n| **Pyelo** | **ë³µì¡ / ì„ì‚°ë¶€** | **IV** Ceftriaxone | 14ì¼ | **ë¬´ì¡°ê±´ ì…ì›**. 72hr ì—´ ì§€ì†ì‹œ CT. |\n## 4. âš¡ Exam High-Yield Summary\n1. **Sterile Pyuria (ê·  ì—†ëŠ” ë†ë‡¨):** ì†Œë³€ê²€ì‚¬ ì—¼ì¦(WBC) ìˆëŠ”ë° ë°°ì–‘ ìŒì„±? ğŸ‘‰ **Chlamydia/Gonorrhea (STD)** ì˜ì‹¬!\n2. **ë‚¨ì UTI:** ë¬´ì¡°ê±´ **Complicated**ë¡œ ê°„ì£¼í•˜ê³  ê²€ì‚¬ ëŒë ¤ë¼. (ì „ë¦½ì„ ì—¼, í•´ë¶€í•™ì  ì´ìƒ)\n3. **Recurrent UTI (ì¬ë°œì„±):** ì„±ê´€ê³„ í›„ ì¬ë°œí•˜ë©´ **ì„±ê´€ê³„ ì§í›„ ì˜ˆë°©ì  í•­ìƒì œ(1íšŒ)**ê°€ íš¨ê³¼ì .","subject":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","page_title":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","episode":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","section_path":["UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb"],"source_doc_id":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","source_page":null,"source_anchor":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb-1","focus_area":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","tags":["usmle-step2","core"]}
{"chunk_type":"transcript_chunk","text":"# LM_endo 2\n\"Okay, let's get straight to it. You are deep in the weeds of USMLE Step 2 prep. You've gotten through the big adult systems, you're feeling okay about cardiology, pulmo, and then, uh, you hit pediatric endocrinology. Right. And the temptation is to just think, okay, same hormones, just smaller doses. Which is, I mean, it's the fastest way to get questions wrong on the exam. Exactly. Looking at this stack of notes you've pulled, it is so clear that endocrine peds isn't just scaling things down. It's, you know, it's...\"\n---\n# USMLE Step 2 Pediatric Endocrinology Deep Dive ê°•ì˜ë¡\n## 1. Introduction: ì„±ì¸ ë‚´ë¶„ë¹„í•™ê³¼ì˜ ì°¨ì´ì \nì´ ê°•ì˜ì˜ í•µì‹¬ì€ ì†Œì•„ ë‚´ë¶„ë¹„í•™ì„ ë‹¨ìˆœíˆ \"ì„±ì¸ì˜ ì¶•ì†ŒíŒ(same hormones, smaller doses)\"ìœ¼ë¡œ ìƒê°í•˜ë©´ ì‹œí—˜ì—ì„œ í‹€ë¦°ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê°€ì¥ ì¤‘ìš”í•œ í…Œë§ˆëŠ” **\"ëª¨ì²´-íƒœì•„ ì¸í„°í˜ì´ìŠ¤(Maternal-Fetal Interface)\"**ì…ë‹ˆë‹¤.\n- ì„±ì¸ ì˜í•™: ëˆˆì•ì˜ í™˜ìë¥¼ ì¹˜ë£Œí•¨.\n- ì†Œì•„ ë‚´ë¶„ë¹„í•™(íŠ¹íˆ ì‹ ìƒì•„): ì¢…ì¢… **ì–´ë¨¸ë‹ˆì˜ ìƒë¦¬í•™ì  ìƒíƒœì— ëŒ€í•œ \"ë°˜í–¥(Echo)\"**ì„ ì¹˜ë£Œí•˜ëŠ” ê²ƒì„. ì´ ì—°ê²°ê³ ë¦¬ë¥¼ ë†“ì¹˜ë©´ ì§„ë‹¨ì„ ë†“ì¹˜ê²Œ ë©ë‹ˆë‹¤.\n---\n## 2. í•´ë¶€í•™ì  êµ¬ì¡°ì™€ ê°‘ìƒì„  (Neck Anatomy & Thyroid)\n### â˜… Clinical Scenario: Midline Neck Mass\n- **ìƒí™©:** í•™ë ¹ê¸° ì•„ë™ì´ ëª© ì¤‘ì•™(midline)ì— ë©ì–´ë¦¬ê°€ ë§Œì ¸ì ¸ì„œ ë‚´ì›. ì¹¨ì„ ì‚¼í‚¬ ë•Œ ë©ì–´ë¦¬ê°€ ì›€ì§ì„.\n- **ì „í˜•ì ì¸ ìƒê°:** ê°‘ìƒì„  ì„¤ê´€ ë‚­ì¢…(Thyroglossal duct cyst) â†’ ìˆ˜ìˆ ë¡œ ì œê±°í•´ì•¼ì§€!\n- **í•¨ì •(Trap):** ë‹¨ìˆœ ë‚­ì¢…ì´ ì•„ë‹ˆë¼ **ì´ì†Œì„± ê°‘ìƒì„  ì¡°ì§(Ectopic Thyroid Tissue)**ì¼ ìˆ˜ ìˆìŒ.\n    - ë°œìƒí•™ì ìœ¼ë¡œ ê°‘ìƒì„ ì´ í˜€ ê¸°ì €ë¶€ì—ì„œ ëª©ìœ¼ë¡œ ë‚´ë ¤ì˜¤ë‹¤ê°€ ì¤‘ê°„ì— ë©ˆì¶˜ ê²ƒ.\n    - ì¤‘ìš”í•œ ì ì€ ì´ ë©ì–´ë¦¬ê°€ ì•„ì´ì˜ **ìœ ì¼í•œ ê¸°ëŠ¥ì„± ê°‘ìƒì„  ì¡°ì§**ì¼ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒ.\n- **ìœ„í—˜ì„±:** í™•ì¸ ì—†ì´ ìˆ˜ìˆ ë¡œ ì œê±°í•˜ë©´ ì•„ì´ëŠ” í‰ìƒ **ì˜êµ¬ì ì¸ ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦(Permanent Hypothyroidism)**ì„ ê°–ê²Œ ë¨. ì¬ì•™(Disaster).\n- **Next Best Step:**\n    1. ì ˆëŒ€ ë°”ë¡œ ìˆ˜ìˆ í•˜ì§€ ë§ ê²ƒ.\n    2. **ì´ˆìŒíŒŒ(Ultrasound) & TSH/T4 í™•ì¸:** ì •ìƒ ìœ„ì¹˜ì— ê°‘ìƒì„ ì´ ì¡´ì¬í•˜ëŠ”ì§€ ë¨¼ì € í™•ì¸(Map the territory)í•´ì•¼ í•¨.\n    3. ì´ì†Œì„± ì¡°ì§ì¼ ê²½ìš° ê¸°ëŠ¥ì´ ë¶ˆì™„ì „í•˜ì—¬ ì´ë¯¸ TSHê°€ ë†’ì„ ìˆ˜ ìˆìŒ(Hypothyroid).\n---\n## 3. ì„ì‹  ì¤‘ ê°‘ìƒì„  ìƒë¦¬í•™ (Maternal-Fetal Interface)\nì„ì‹ ì€ ê°‘ìƒì„ ì— ëŒ€í•œ \"ìŠ¤íŠ¸ë ˆìŠ¤ í…ŒìŠ¤íŠ¸\"ì™€ ê°™ìŠµë‹ˆë‹¤. ì„ì‹ ë¶€ì˜ ê²€ì‚¬ ìˆ˜ì¹˜ëŠ” ë¹„ì„ì‹  ê¸°ì¤€ìœ¼ë¡œëŠ” ë¹„ì •ìƒì²˜ëŸ¼ ë³´ì¼ ìˆ˜ ìˆìœ¼ë‚˜ ìƒë¦¬í•™ì ìœ¼ë¡œëŠ” ì •ìƒì…ë‹ˆë‹¤.\n### ë‘ ê°€ì§€ ì£¼ìš” í˜¸ë¥´ëª¬ì˜ ì‘ìš©\n1. **ì—ìŠ¤íŠ¸ë¡œê²(Estrogen):**\n    - ê°„ì—ì„œ **TBG(Thyroxine Binding Globulin)** ìƒì„±ì„ ì¦ê°€ì‹œí‚´.\n    - ê²°ê³¼: **Total T4 ì¦ê°€** (ë‹¨ë°±ì§ˆ ê²°í•© í˜¸ë¥´ëª¬ì´ ëŠ˜ì–´ë‚¬ìœ¼ë¯€ë¡œ). Free T4ëŠ” ì •ìƒ ìœ ì§€.\n    - â˜… ì„ì‹ ë¶€ì—ì„œ Total T4ê°€ ë†’ì€ ê²ƒì€ ìƒë¦¬í•™ì  ì •ìƒ ì†Œê²¬ì´ë¯€ë¡œ ì¹˜ë£Œí•˜ì§€ ì•ŠìŒ.\n2. **hCG (Human Chorionic Gonadotropin):**\n    - hCGì™€ TSHëŠ” ë™ì¼í•œ Alpha subunitì„ ê³µìœ í•¨ (ì‚¬ì´Œ ì§€ê°„).\n    - ì„ì‹  1ë¶„ê¸°ì— hCGê°€ í”¼í¬ë¥¼ ì¹  ë•Œ TSH ìˆ˜ìš©ì²´ë¥¼ ìê·¹(Weak TSH ì—­í• ).\n    - ê²°ê³¼: T4 ì•½ê°„ ì¦ê°€ â†’ í”¼ë“œë°±ìœ¼ë¡œ **TSH ê°ì†Œ**.\n    - ì„ìƒì  ì˜ì˜: **ì„ì‹ ì„± ì¼ê³¼ì„± ê°‘ìƒì„ ì¤‘ë…ì¦(Gestational Transient Thyrotoxicosis)**. ì…ë§ì´ ì‹¬í•œ(Hyperemesis Gravidarum) ì‚°ëª¨ì—ì„œ hCGê°€ ë§¤ìš° ë†’ì•„ ë°œìƒ ê°€ëŠ¥.\n### â˜… Graves' Disease in Pregnancy (ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ ì‚°ëª¨ ê´€ë¦¬) â†’ ëœ! ì¹˜ë£Œí•œë‹¤!\nì‚°ëª¨ê°€ ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ìœ¼ë¡œ í•­ê°‘ìƒì„ ì œ(PTU, Methimazole)ë¥¼ ë³µìš©í•´ì•¼ í•  ë•Œ ë”œë ˆë§ˆê°€ ë°œìƒí•©ë‹ˆë‹¤.\n- **ë¬¸ì œ:** ì•½ë¬¼ì´ íƒœë°˜ì„ í†µê³¼í•¨. íƒœì•„ì˜ ê°‘ìƒì„ ì€ í›¨ì”¬ ì‘ê³  ì˜ˆë¯¼í•¨.\n- **ê³¼ì‰ ì¹˜ë£Œì˜ ìœ„í—˜:** ì‚°ëª¨ ìˆ˜ì¹˜ë¥¼ ì™„ë²½í•˜ê²Œ ì •ìƒìœ¼ë¡œ ë§ì¶”ë ¤ë‹¤ íƒœì•„ì—ê²Œ ì•½ë¬¼ì´ ê³¼ë‹¤ ì „ë‹¬ë˜ë©´, íƒœì•„ì˜ ê°‘ìƒì„ ì´ ì–µì œë¨ â†’ íƒœì•„ ë‡Œí•˜ìˆ˜ì²´ê°€ TSHë¥¼ ë¿œì–´ëƒ„ â†’ **íƒœì•„ ê°‘ìƒì„ ì¢…(Fetal Goiter)** ë° ì„ ì²œì„± ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦ ìœ ë°œ.\n- **ì „ëµ:** **\"Permissive Hyperthyroidism\" (í—ˆìš©ì  ê°‘ìƒì„  í•­ì§„)**. ì‚°ëª¨ë¥¼ ì•½ê°„ ê°‘ìƒì„  í•­ì§„ ìƒíƒœ(mildly hyperthyroid)ë¡œ ìœ ì§€í•˜ì—¬ íƒœì•„ë¥¼ ê³¼ì‰ ì¹˜ë£Œë¡œë¶€í„° ë³´í˜¸í•˜ëŠ” ì•ˆì „ì¥ì¹˜(Safety buffer)ë¥¼ ë‘ .","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-1","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","treatment"]}
{"chunk_type":"transcript_chunk","text":"### Neonatal Thyrotoxicosis (ì‹ ìƒì•„ ê°‘ìƒì„  ì¤‘ë…ì¦)\n- **ì›ì¸:** ì‚°ëª¨ì˜ IgG í•­ì²´(TSH ìˆ˜ìš©ì²´ ìê·¹ í•­ì²´)ê°€ íƒœë°˜ì„ í†µê³¼í•˜ì—¬ íƒœì•„ ê°‘ìƒì„ ì„ ìê·¹.\n- **ì¦ìƒ:** ë¹ˆë§¥(Tachycardia), ë³´ì±„ëŠ” ì•„ì´(Irritability), ì²´ì¤‘ ì¦ê°€ ë¶€ì§„.\n- **ê²½ê³¼:** ì¼ì‹œì ì„(Transient). ëª¨ì²´ë¡œë¶€í„° ë°›ì€ í•­ì²´ê°€ ì‚¬ë¼ì§€ë©´ ì¢‹ì•„ì§(ìˆ˜ì£¼~ìˆ˜ê°œì›”).\n- **ì¹˜ë£Œ:** ê¸‰ì„±ê¸°ì—ëŠ” ë² íƒ€ì°¨ë‹¨ì œ(Beta-blockers)ë‚˜ ë©”í‹°ë§ˆì¡¸ë¡œ ì¦ìƒ ì¡°ì ˆ í•„ìš”.\n---\n## 4. ì¹¼ìŠ˜ ëŒ€ì‚¬ ë¯¸ìŠ¤í„°ë¦¬ (Calcium Mysteries)\n### â˜… Clinical Scenario: Seizing Newborn\n- **ìƒí™©:** ìƒí›„ 3-4ì¼ ëœ ì‹ ìƒì•„ê°€ ê²½ë ¨(Seizure/Jittery)ìœ¼ë¡œ ë‚´ì›.\n- **ê²€ì‚¬ ê²°ê³¼:** **ì €ì¹¼ìŠ˜í˜ˆì¦(Hypocalcemia)**, PTH ë‚®ê±°ë‚˜ ë¶€ì ì ˆí•˜ê²Œ ì •ìƒ(Low/Normal PTH).\n- **ê°ë³„ ì§„ë‹¨:**\n    - DiGeorge Syndrome (22q11 deletion): í‰ì„ (Thymus) ì—†ìŒ, ì‹¬ì¥ ê¸°í˜• ë™ë°˜. í•˜ì§€ë§Œ ì´ ì‹œë‚˜ë¦¬ì˜¤ì—ì„œëŠ” í‰ì„ ë„ ìˆê³  ì‹¬ì¥ë„ ì •ìƒì„.\n- **ì§„ë‹¨:** **Maternal Familial Hypocalciuric Hypercalcemia (FHH, ê°€ì¡±ì„± ì €ì¹¼ìŠ˜ë‡¨ì„± ê³ ì¹¼ìŠ˜í˜ˆì¦)**\n- **ê¸°ì „ (Mechanism):**\n    1. **ì‚°ëª¨:** ì¹¼ìŠ˜ ê°ì§€ ìˆ˜ìš©ì²´(Ca-sensing receptor)ê°€ ë‘”ê°í•¨(Set pointê°€ ë†’ìŒ). ì‚°ëª¨ëŠ” ê³ ì¹¼ìŠ˜í˜ˆì¦ì´ ìˆì§€ë§Œ ì¦ìƒì€ ì—†ìŒ(Asymptomatic).\n    2. **íƒœì•„:** ì‚°ëª¨ì˜ ë†’ì€ ì¹¼ìŠ˜ì´ íƒœë°˜ì„ í†µê³¼í•´ íƒœì•„ì—ê²Œ ì „ë‹¬ë¨. íƒœì•„ì˜ ë¶€ê°‘ìƒì„ (Parathyroid)ì€ \"ì¹¼ìŠ˜ì´ ì¶©ë¶„í•˜ë„¤\"ë¼ê³  ìƒê°í•˜ê³  **í™œë™ì„ ë©ˆì¶¤(Suppressed/Dormant)**.\n    3. **ì¶œìƒ:** íƒ¯ì¤„ì´ ëŠê¸°ë©° ì¹¼ìŠ˜ ê³µê¸‰ ì¤‘ë‹¨. í•˜ì§€ë§Œ ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì€ ì—¬ì „íˆ ì ë“¤ì–´ ìˆìŒ.\n    4. **ê²°ê³¼:** ì•„ê¸°ì˜ ì¹¼ìŠ˜ ìˆ˜ì¹˜ê°€ ê¸‰ë½í•˜ë©° ê²½ë ¨ ë°œìƒ.\n- **í™•ì§„ ë°©ë²•:** **ì‚°ëª¨ì˜ ì†Œë³€**ì„ ê²€ì‚¬í•¨. ì‚°ëª¨ì˜ ì†Œë³€ ì¹¼ìŠ˜ì´ ë§¤ìš° ë‚®ìŒ (Low urine calcium).\n- **ì¹˜ë£Œ:** ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì´ ê¹¨ì–´ë‚  ë•Œê¹Œì§€ ì§€ì§€ì  ì¹˜ë£Œ(ì¹¼ìŠ˜, ë¹„íƒ€ë¯¼ D).\n---\n## 5. ë¶€ì‹  ì§ˆí™˜ (Adrenal Glands - CAH)\nì„ ì²œì„± ë¶€ì‹  ê³¼í˜•ì„±(CAH)ì—ì„œ ê°€ì¥ í”í•œ 21-hydroxylase ê²°í•(ì €í˜ˆì••, ê³ ì¹¼ë¥¨í˜ˆì¦) ì™¸ì—, **ê³ í˜ˆì••**ì„ ìœ ë°œí•˜ëŠ” ìœ í˜•ì„ êµ¬ë³„í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤.\n### ê³ í˜ˆì••ì„ ìœ ë°œí•˜ëŠ” CAH ìœ í˜• (Hypertensive Forms)\n| ìœ í˜• | íš¨ì†Œ ê²°í• | ì£¼ìš” íŠ¹ì§• ë° ê¸°ì „ | ì„±ì  ë°œë‹¬ (Sexual Development) |\n| --- | --- | --- | --- |\n| **11Î²-Hydroxylase Deficiency** | 11Î²-OH | ëŒì´ í•˜ë¥˜ì— ìˆìŒ.<br>DOC(11-Deoxycorticosterone) ì¶•ì .<br>DOCëŠ” ì•Œë„ìŠ¤í…Œë¡ ì²˜ëŸ¼ ì‘ìš© â†’ ì—¼ë¶„/ìˆ˜ë¶„ ì €ë¥˜ â†’ **ê³ í˜ˆì••, ì €ì¹¼ë¥¨í˜ˆì¦** | **ë‚¨ì„±íšŒ(Virilization)**<br>(ì•ˆë“œë¡œê² ê²½ë¡œë¡œ ë„˜ì¹¨)<br>ì—¬ì•„ì˜ ëª¨í˜¸í•œ ì„±ê¸°(Ambiguous genitalia) |\n| **17Î±-Hydroxylase Deficiency** | 17Î±-OH | ì„±í˜¸ë¥´ëª¬ ìƒì„± ë¶ˆê°€.<br>ë¯¸ë„¤ë„ì½”ë¥´í‹°ì½”ì´ë“œ ê³¼ì‰ â†’ **ê³ í˜ˆì••, ì €ì¹¼ë¥¨í˜ˆì¦** | **ì„±ì  ìœ ì¹˜ì¦(Sexually Infantile)**<br>ì‚¬ì¶˜ê¸° ì—†ìŒ, ì„±í˜¸ë¥´ëª¬ ì—†ìŒ |\n### â˜… Pharmacology Pearl: Etomidate\n- ë§ˆì·¨ ìœ ë„ì œì¸ **Etomidate**ëŠ” **11Î²-Hydroxylaseë¥¼ ì–µì œ**í•¨.\n- ìœ ì „ì  ì§ˆí™˜ê³¼ ìœ ì‚¬í•œ íš¨ê³¼ë¥¼ ëƒ„(Cortisol ìƒì„± ì°¨ë‹¨).\n- **ì£¼ì˜:** íŒ¨í˜ˆì¦(Sepsis)ì´ë‚˜ ë¶€ì‹  ì˜ˆë¹„ë ¥(Adrenal reserve)ì´ ë–¨ì–´ì§„ í™˜ìì—ê²Œ ì‚¬ìš©í•˜ë©´ **ê¸‰ì„± ë¶€ì‹  ë¶€ì „(Acute Adrenal Crisis)**ì„ ìœ ë°œí•  ìˆ˜ ìˆìœ¼ë¯€ë¡œ ê¸ˆê¸°(Contraindication).\n---\n## 6. ì†Œì•„ ë‹¹ë‡¨ë³‘ (Pediatric Diabetes)\n### íŒ¨ëŸ¬ë‹¤ì„ì˜ ë³€í™”\n- ê³¼ê±°: ì†Œì•„ = 1í˜• ë‹¹ë‡¨.\n- í˜„ì¬: ë¹„ë§Œ ìœ í–‰ìœ¼ë¡œ ì²­ì†Œë…„ ë° ì†Œì•„ì—ì„œ 2í˜• ë‹¹ë‡¨ ê¸‰ì¦. 1í˜•ê³¼ 2í˜•ì„ êµ¬ë³„í•˜ëŠ” ê²ƒì´ í•„ìˆ˜ì .\n### êµ¬ë³„ ë°©ë²•: C-Peptide & Antibodies\n1. **C-Peptide:** ì¸ìŠë¦°ì´ ë§Œë“¤ì–´ì§ˆ ë•Œ 1:1ë¡œ ìƒì„±ë˜ëŠ” ì—°ê²° ì¡°ê°(Wrapper). ë‚´ì¸ì„± ì¸ìŠë¦° ìƒì„±ì˜ ì§€í‘œ.\n    - **1í˜• ë‹¹ë‡¨:** ê³µì¥ì´ ë¶ˆíƒ. ì¸ìŠë¦° ì—†ìŒ â†’ **C-Peptide ë‚®ê±°ë‚˜ ì—†ìŒ**.\n    - **2í˜• ë‹¹ë‡¨:** ì¸ìŠë¦° ì €í•­ì„±. ì·Œì¥ì´ ê³¼ë¡œí•¨ â†’ ì¸ìŠë¦° ë†’ìŒ â†’ **C-Peptide ë†’ìŒ**.\n2. **ìê°€í•­ì²´ (Autoantibodies):**\n    - **1í˜•:** GAD65, IA-2 ë“± í•­ì²´ ì–‘ì„±.\n    - **2í˜•:** í•­ì²´ ìŒì„±.\n### MODY (Maturity Onset Diabetes of the Young)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-21","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"- íŠ¹ì§•: ì Šì€ ë‚˜ì´, ê²½ë¯¸í•œ ê³ í˜ˆë‹¹, **ê°•í•œ ê°€ì¡±ë ¥**, ë¹„ë§Œ ì•„ë‹˜, í•­ì²´ ìŒì„±.\n- ì›ì¸: ë‹¨ì¼ ìœ ì „ì ëŒì—°ë³€ì´(Monogenic defect). ìê°€ë©´ì—­ ì•„ë‹˜.\n- ì¹˜ë£Œ: ì¼ë¶€ ìœ í˜•(MODY 1)ì€ ì¸ìŠë¦° ëŒ€ì‹  **ì„¤í¬ë‹ìš°ë ˆì•„(Sulfonylureas)**ì— ë°˜ì‘ì´ ì¢‹ìŒ.\n---\n## 7. Rapid Fire Recap (í•µì‹¬ ìš”ì•½)\nê°•ì˜ ë‚´ìš©ì„ 5ê°€ì§€ í•µì‹¬ í¬ì¸íŠ¸ë¡œ ì •ë¦¬í•©ë‹ˆë‹¤.\n1. **Midline Neck Mass:** ì ˆëŒ€ ë°”ë¡œ ì ˆì œí•˜ì§€ ë§ˆë¼. **ì´ˆìŒíŒŒì™€ TSH**ë¡œ ì´ì†Œì„± ê°‘ìƒì„  ì—¬ë¶€ë¥¼ ë¨¼ì € í™•ì¸í•´ë¼.\n2. **Pregnancy Thyroid Physiology:** Estrogenì€ TBGë¥¼ ë†’ì—¬ Total T4ë¥¼ ë†’ì´ê³ , hCGëŠ” TSHë¥¼ í‰ë‚´ë‚´ì–´ TSHë¥¼ ë‚®ì¶˜ë‹¤. Gravesë³‘ ì‚°ëª¨ ì¹˜ë£Œ ì‹œ íƒœì•„ì˜ ê°‘ìƒì„  ì €í•˜ë¥¼ ë§‰ê¸° ìœ„í•´ ì‚°ëª¨ë¥¼ ì•½ê°„ í•­ì§„ ìƒíƒœë¡œ ìœ ì§€í•´ë¼.\n3. **Seizing Newborn:** ì €ì¹¼ìŠ˜í˜ˆì¦ + ë‚®ì€/ì •ìƒ PTH ì‹ ìƒì•„ë¥¼ ë³´ë©´ **ì—„ë§ˆì˜ ì†Œë³€ ì¹¼ìŠ˜**ì„ í™•ì¸í•´ë¼(Maternal FHH).\n4. **Adrenal Hypertension:** ê³ í˜ˆì•• + ë‚¨ì„±í™”(Virilization) = **11Î²-hydroxylase ê²°í•**. ê³ í˜ˆì•• + ì„±ì  ë¯¸ì„±ìˆ™ = **17Î±-hydroxylase ê²°í•**. (EtomidateëŠ” 11Î² íš¨ì†Œë¥¼ ì°¨ë‹¨í•¨).\n5. **Pediatric Diabetes:** ë‚˜ì´ë‚˜ ì²´í˜•ë§Œ ë³´ì§€ ë§ê³  **C-Peptideì™€ í•­ì²´**ë¥¼ í†µí•´ 1í˜•ê³¼ 2í˜•ì„ êµ¬ë³„í•´ë¼. MODY(ê°•í•œ ê°€ì¡±ë ¥, í•­ì²´ ìŒì„±) ê°€ëŠ¥ì„±ë„ ì—¼ë‘ì— ë‘¬ë¼.\n**Final Thought:** ì†Œì•„ê³¼ í™˜ìëŠ” ì¢…ì¢… **ì–´ë¨¸ë‹ˆì˜ ê±°ìš¸(Mirror of the mother)**ì…ë‹ˆë‹¤. ì„¤ëª…ë˜ì§€ ì•ŠëŠ” ì‹ ìƒì•„ì˜ ì¦ìƒì„ ë³¼ ë•Œ í•­ìƒ ëª¨ì²´ì˜ ìƒíƒœë¥¼ ì—­ì¶”ì (Trace the pathway)í•´ë³´ì„¸ìš”.\n---\n# ğŸ©º USMLE Step 2: The Pancreas Operational Framework\n## 1. Introduction: The Mental Model Shift\nUSMLE Step 2 ì‹œí—˜ì€ ë‹¨ìˆœí•œ ìƒë¦¬í•™(ì¸ìŠë¦° íŒí”„ ê°œë…)ì„ ë„˜ì–´ **ì„ìƒ ê´€ë¦¬(Clinical Management)**ì™€ **ë¯¸ë¬˜í•œ ì„ ë³„ ê°€ì´ë“œë¼ì¸(Screening Guidelines)**ì— ì´ˆì ì„ ë§ì¶¥ë‹ˆë‹¤.\nì´ ê°•ì˜ëŠ” ê²‰ë³´ê¸°ì— ë¹„ìŠ·í•´ ë³´ì´ì§€ë§Œ ì™„ì „íˆ ë‹¤ë¥¸ ì¹˜ë£Œê°€ í•„ìš”í•œ í™˜ìë“¤ì„ êµ¬ë³„í•˜ëŠ” **\"Grey Area(ì„ìƒì  íŒë‹¨)\"** ëŠ¥ë ¥ì„ í‚¤ìš°ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤.\n**ğŸ“‹ ê°•ì˜ ë¡œë“œë§µ:**\n1. **Framework:** ë‹¹ë‡¨ë³‘ ì•„í˜•(Subtypes) ë¶„ë¥˜ ë° êµ¬ë³„ë²•\n2. **Diagnosis & Screening:** ìˆ˜ì¹˜, ì»·ì˜¤í”„(Cut-offs), ê°€ì´ë“œë¼ì¸\n3. **Health Maintenance:** ëª¨ë“  ë‹¹ë‡¨ í™˜ì ë°©ë¬¸ ì‹œ í™•ì¸í•´ì•¼ í•  ì •ì‹ ì  ì²´í¬ë¦¬ìŠ¤íŠ¸\n4. **Complications:** ì‹ ê²½ë³‘ì¦(Neuropathy)ê³¼ ìœ„ë§ˆë¹„(Gastroparesis) ì‹¬ì¸µ ë¶„ì„\n5. **Acute Decompensation:** ë‹¹ë‡¨ë³‘ì„± ì¼€í†¤ì‚°ì¦(DKA)\n---\n## 2. Building the Framework: Subtypes of Diabetes\nâ˜… **í•µì‹¬ ê·œì¹™:** í™˜ìì˜ ë‚˜ì´ë§Œ ë³´ê³  ë‹¹ë‡¨ë³‘ ìœ í˜•ì„ ê°€ì •í•˜ì§€ ë§ˆì‹­ì‹œì˜¤(ì†Œì•„ ë¹„ë§Œ ì¦ê°€ë¡œ ì†Œì•„ 2í˜• ë‹¹ë‡¨ ê¸‰ì¦). \"ìƒí™”í•™ì  ì¦ê±°\"ë¥¼ í†µí•´ ì¼€ì´ìŠ¤ë¥¼ êµ¬ì¶•í•´ì•¼ í•©ë‹ˆë‹¤.\n### ğŸ§¬ C-Peptide: The Key Differentiator\n- ì·Œì¥ì€ Pro-insulinì„ ë§Œë“¤ê³ , ì´ê²ƒì´ ë¶„í•´ë˜ì–´ **Insulin**ê³¼ **C-Peptide**ê°€ 1:1 ë¹„ìœ¨ë¡œ í˜ˆë¥˜ë¡œ ë°©ì¶œë©ë‹ˆë‹¤.\n- **C-Peptide ì¸¡ì •** = ë‚´ì¸ì„± ì¸ìŠë¦°(Endogenous Insulin) ìƒì‚°ëŸ‰ ì¸¡ì •.\n| êµ¬ë¶„ | Type 1 Diabetes (ìê°€ë©´ì—­) | Type 2 Diabetes (ì €í•­ì„±) |\n| --- | --- | --- |\n| **ê¸°ì „** | ìê°€ë©´ì—­ ê³µê²©ìœ¼ë¡œ ë² íƒ€ì„¸í¬ íŒŒê´´ (Factory burned down) | ì¸ìŠë¦° ì €í•­ì„±(Shipping blocked) â†’ ì·Œì¥ì´ ë³´ìƒì ìœ¼ë¡œ ì¸ìŠë¦° ê³¼ë‹¤ ë¶„ë¹„ |\n| **ì„ìƒ ì–‘ìƒ** | ê¸‰ì„±(Acute), ì‹¬í•œ ë‹¤ë‡¨/ë‹¤ìŒ, ì²´ì¤‘ ê°ì†Œ, DKAë¡œ ë‚´ì› | ì„œì„œíˆ ì§„í–‰(Insidious), ë¬´ì¦ìƒì¼ ìˆ˜ ìˆìŒ |\n| **â˜… C-Peptide** | **Undetectable (ê²€ì¶œ ë¶ˆê°€) / ë§¤ìš° ë‚®ìŒ** | **Normal or Elevated (ì´ˆê¸°)** |\n| **Antibodies** | **Positive** (GAD65 - Glutamic Acid Decarboxylase) | **Negative** |\n### ğŸ§© The Curveball: Monogenic Diabetes (MODY)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-41","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"- **ì‹œë‚˜ë¦¬ì˜¤:** ì Šê³  ë§ˆë¥¸ í™˜ì(24ì„¸, BMI 21), ê²½ë¯¸í•œ ê³ í˜ˆë‹¹.\n- **í•¨ì •:** 1í˜•ì²˜ëŸ¼ ë³´ì´ì§€ë§Œ(ì Šê³  ë§ˆë¦„), í•­ì²´ ê²€ì‚¬ê°€ ìŒì„±ì…ë‹ˆë‹¤.\n- **íŠ¹ì§•:**\n    - GAD65 Antibodies: **Negative** (ìê°€ë©´ì—­ ì•„ë‹˜)\n    - C-Peptide: **Detectable** (ì¸ìŠë¦° ìƒì‚°ì€ í•¨, ë¶„ë¹„ ê¸°ì „ì˜ ìœ ì „ì  ê²°í•¨ - Software problem)\n    - ê°€ì¡±ë ¥: **Autosomal Dominant (ìƒì—¼ìƒ‰ì²´ ìš°ì„±)** - 3ì„¸ëŒ€ì— ê±¸ì¹œ ìˆ˜ì§ ê°ì—¼ íŒ¨í„´.\n- **ì¹˜ë£Œ:** ì¸ìŠë¦° ì£¼ì‚¬ê°€ í•„ìš” ì—†ëŠ” ê²½ìš°ê°€ ë§ìŒ. ì„¤í¬ë‹ìš°ë ˆì•„(Sulfonylureas)ì— ë°˜ì‘ì´ ì¢‹ìŒ.\n---\n## 3. Diagnosis and Screening Game\n### ğŸ•µï¸â€â™‚ï¸ Who to Screen? (USPSTF Guidelines)\n- **ê¸°ë³¸:** 35~70ì„¸ ì„±ì¸ ì¤‘ ê³¼ì²´ì¤‘ ë˜ëŠ” ë¹„ë§Œ(BMI > 25)ì¸ ê²½ìš°.\n- **â˜… 35ì„¸ ë¯¸ë§Œ ì˜ˆì™¸ ì¡°í•­ (Under 35 Exception):** ê³¼ì²´ì¤‘ì´ë©´ì„œ ì¶”ê°€ ìœ„í—˜ ìš”ì¸ì´ ìˆëŠ” ê²½ìš° ì¦‰ì‹œ ì„ ë³„ ê²€ì‚¬.\n    - **HIV ê°ì—¼:** ë°”ì´ëŸ¬ìŠ¤ ìì²´ì˜ ì—¼ì¦ ë° í•­ë ˆíŠ¸ë¡œë°”ì´ëŸ¬ìŠ¤ì œ(ì•½ë¬¼)ì˜ ëŒ€ì‚¬ ë…ì„±.\n    - **ë‚­í¬ì„± ì„¬ìœ ì¦ (Cystic Fibrosis)**\n    - **ì¥ê¸° ì´ì‹ í›„ (Post-organ transplantation):** ë©´ì—­ì–µì œì œ(Tacrolimus, Cyclosporine, â˜…Steroids) ì‚¬ìš© ë•Œë¬¸. ìŠ¤í…Œë¡œì´ë“œëŠ” ê°„ì˜ í¬ë„ë‹¹ ìƒì„±ì„ ë†’ì´ê³  ê·¼ìœ¡ì˜ ì¸ìŠë¦° ì €í•­ì„±ì„ ìœ ë°œí•¨.\n    - **ì„ì‹  ê³„íš ì¤‘ì¸ ì—¬ì„±:** PCOS, ê°€ì¡±ë ¥ ë“± ìœ„í—˜ ìš”ì¸ì´ ìˆë‹¤ë©´ ì„ì‹  ì „ ê²€ì‚¬ í•„ìˆ˜.\n### ğŸ“Š Diagnostic Cut-offs (ìˆ˜ì¹˜ ì•”ê¸° í•„ìˆ˜)\n1. **Hemoglobin A1c:**\n    - **Diabetes:** â‰¥ 6.5%\n    - Pre-diabetes: 5.7% ~ 6.4%\n2. **Fasting Plasma Glucose (8ì‹œê°„ ê³µë³µ):**\n    - **Diabetes:** â‰¥ 126 mg/dL (ë§ë§‰ë³‘ì¦ ìœ ë³‘ë¥ ì´ ê¸‰ì¦í•˜ëŠ” êµ¬ê°„)\n    - Pre-diabetes: 100 ~ 125 mg/dL\n3. **Random Glucose (ìœ ì¦ìƒ í™˜ì):**\n    - **Diabetes:** â‰¥ 200 mg/dL + ê³ í˜ˆë‹¹ ì¦ìƒ (ë‹¤ìŒ, ë‹¤ë‡¨, ì²´ì¤‘ê°ì†Œ)\n4. **â˜… OGTT (75g ê²½êµ¬ í¬ë„ë‹¹ ë¶€í•˜ ê²€ì‚¬):**\n    - **Diabetes:** 2ì‹œê°„ í›„ í˜ˆë‹¹ â‰¥ 200 mg/dL\n    - **ì„ìƒì  ì˜ì˜:** **PCOS(ë‹¤ë‚­ì„± ë‚œì†Œ ì¦í›„êµ°)** í™˜ìì—ê²Œ ê°€ì¥ ë¯¼ê°í•œ(Most Sensitive) ê²€ì‚¬. PCOS í™˜ìëŠ” ê³µë³µ í˜ˆë‹¹ì´ë‚˜ A1cê°€ ì •ìƒì´ë¼ë„ ì‹í›„ ì¸ìŠë¦° ì €í•­ì„±ì´ ì‹¬í•  ìˆ˜ ìˆìŒ.\n---\n## 4. Health Maintenance Checklist (The Visit)\nëª¨ë“  ë°©ë¬¸ ì‹œ í™•ì¸í•´ì•¼ í•  ì‹œìŠ¤í…œ ì ê²€ ì‚¬í•­ì…ë‹ˆë‹¤.\n### ğŸ¯ Glycemic Control Goals\n- **ì¼ë°˜ ì„±ì¸:** A1c â‰¤ 7%\n- **â˜… ë…¸ì¸/ë™ë°˜ì§ˆí™˜ì:** A1c â‰¤ 8%\n    - ì´ìœ : **ì €í˜ˆë‹¹(Hypoglycemia)**ì´ ë” ìœ„í—˜í•¨. ë‚™ìƒ(ê³ ê´€ì ˆ ê³¨ì ˆ), ì–´ì§€ëŸ¬ì›€, ë¶€ì •ë§¥ ìœ ë°œ ê°€ëŠ¥. ì¹˜ë£Œê°€ ì§ˆë³‘ë³´ë‹¤ ë” ìœ„í—˜í•  ìˆ˜ ìˆìŒ.\n### ğŸ›¡ï¸ Organ Protection Screening\n1. **Nephropathy (ì‹ ì¥):**\n    - ê²€ì‚¬: ì—° 1íšŒ **Random Urine Albumin-to-Creatinine Ratio (UACR)**.\n    - ê¸°ì¤€: < 30 mg/g (ì •ìƒ). ê·¸ ì´ìƒì€ ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨(Microalbuminuria) â†’ ACE ì–µì œì œ ì‚¬ìš© ê³ ë ¤.\n2. **Retinopathy (ëˆˆ):**\n    - ê²€ì‚¬: ì•ˆê³¼ ì „ë¬¸ì˜ì— ì˜í•œ ì‚°ë™ ê²€ì‚¬(Dilated eye exam).\n    - **â˜… ì‹œê¸° (ì‹œí—˜ ë¹ˆì¶œ):**\n        - **Type 2:** ì§„ë‹¨ **ì¦‰ì‹œ (Right away)** (ì§„ë‹¨ ì „ ì´ë¯¸ ê³ í˜ˆë‹¹ ê¸°ê°„ì´ ê¸¸ì—ˆìŒ).\n        - **Type 1:** ì§„ë‹¨ í›„ **5ë…„ ë’¤**ë¶€í„° (ë§ë§‰ë³‘ì¦ ë°œìƒì— ì‹œê°„ì´ ê±¸ë¦¼).\n3. **Neuropathy (ì‹ ê²½):**\n    - ê²€ì‚¬: ì—° 1íšŒ ë°œ ê²€ì‚¬ (Monofilament + Tuning fork).\n4. **Cardiovascular (ì‹¬í˜ˆê´€):**\n    - í˜ˆì•• ì¡°ì ˆ (<130/80), ì§€ì§ˆ ê´€ë¦¬(Statins), ê¸ˆì—°, ì•„ìŠ¤í”¼ë¦° ë“±. ë‹¹ë‡¨ í™˜ìì˜ ì£¼ ì‚¬ë§ ì›ì¸ì€ ì‹¬ì¥ ì§ˆí™˜ì„.\n---\n## 5. Complications Deep Dive ğŸ¦µğŸ§ ğŸ¤¢\n### âš¡ Neuropathy (ì‹ ê²½ë³‘ì¦)\në‹¨ìˆœíˆ \"ë°œ ì €ë¦¼\"ì´ ì•„ë‹™ë‹ˆë‹¤.\n1. **Cardiovascular Autonomic Neuropathy (DAN):**\n    - **Resting Tachycardia:** ë¯¸ì£¼ì‹ ê²½(Vagal tone) ì†Œì‹¤ë¡œ ì‹¬ë°•ìˆ˜ ì¦ê°€.\n    - **Loss of Nocturnal Dipping:** ë°¤ì— í˜ˆì••ì´ ë–¨ì–´ì§€ì§€ ì•ŠìŒ.\n    - **Postural Hypotension:** ê¸°ë¦½ì„± ì €í˜ˆì••.\n2. **Genitourinary (ë¹„ë‡¨ìƒì‹ê¸°):**\n    - ë°œê¸° ë¶€ì „, ì—­í–‰ì„± ì‚¬ì •.\n    - **Neurogenic Bladder (ì‹ ê²½ì¸ì„± ë°©ê´‘):** ë°©ê´‘ ì¶©ë§Œ ê°ê° ì†Œì‹¤ â†’ ì†Œë³€ì´ ê°€ë“ ì°¨ë„ ëª¨ë¦„ â†’ Overflow Incontinence (ì—­ë¥˜ì„± ìš”ì‹¤ê¸ˆ) â†’ ì¦ì€ ìš”ë¡œê°ì—¼(UTI).\n3. **Peripheral Neuropathy (ë§ì´ˆ):**\n    - **ê²€ì‚¬ ë„êµ¬:**\n        - **Monofilament (10g force):** ì••ê°(Pressure sensation) ì¸¡ì •. ê¶¤ì–‘(Ulcer) ë°œìƒ ìœ„í—˜ ì˜ˆì¸¡ì— ì¤‘ìš”.\n        - **Tuning Fork:** ì§„ë™ê°ê°(Vibratory sense) ì¸¡ì •. ëŒ€ì„¬ìœ  ì‹ ê²½ ì†ìƒì˜ ì´ˆê¸° ì§•í›„.\n    - **Charcot Arthropathy:** ê°ê° ì†Œì‹¤ë¡œ ì¸í•œ ë¼ˆì™€ ê´€ì ˆì˜ íŒŒê´´. **\"Rocker bottom foot\"** ë³€í˜• ìœ ë°œ.\n### ğŸ¤¢ Gastroparesis (ìœ„ë§ˆë¹„)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-61","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","tree"]}
{"chunk_type":"transcript_chunk","text":"- **ì •ì˜:** ë¯¸ì£¼ì‹ ê²½ ì†ìƒìœ¼ë¡œ ìœ„ ë°°ì¶œì´ ì§€ì—°ë¨.\n- **ì¦ìƒ:** ì˜¤ì‹¬, êµ¬í† , ì¡°ê¸° í¬ë§Œê°.\n- **â˜… \"A-ha\" Vignette Clue (ì‹œí—˜ ê²°ì •ì  ë‹¨ì„œ):**\n    - ì¸ìŠë¦° ì˜ì¡´ì„± ë‹¹ë‡¨ í™˜ìê°€ ì‹í›„ ì˜¤ì‹¬/êµ¬í† ë¥¼ í˜¸ì†Œí•˜ë©° **\"ì‹í›„ ì €í˜ˆë‹¹(Post-prandial Hypoglycemia)\"**ì„ ê²ªìŒ.\n    - **ê¸°ì „ (Mismatch):** ì†íš¨ì„± ì¸ìŠë¦°ì€ íˆ¬ì—¬ë˜ì–´ ì‘ìš©(Peak)í•˜ì§€ë§Œ, ìœ„ë§ˆë¹„ë¡œ ìŒì‹ì€ ì†Œí™”/í¡ìˆ˜ë˜ì§€ ì•ŠìŒ â†’ í˜ˆë‹¹ì„ ì˜¬ë¦´ ìŒì‹ì´ ì—†ëŠ”ë° ì¸ìŠë¦°ë§Œ ì‘ìš©í•˜ì—¬ ì €í˜ˆë‹¹ ë°œìƒ.\n---\n## 6. Acute Decompensation: DKA (Diabetic Ketoacidosis)\n### ğŸš¨ Clinical Presentation\n- **í™˜ì:** ì£¼ë¡œ ì Šì€ 1í˜• ë‹¹ë‡¨ í™˜ì (Brittle diabetes).\n- **ì´ˆê¸° ì¦ìƒ:** ê·¹ì‹¬í•œ ë‹¤ë‡¨, ë‹¤ìŒ, **ì‹œë ¥ ì €í•˜(Blurred Vision)**.\n    - *ì‹œë ¥ ì €í•˜ ì´ìœ :* ê³ í˜ˆë‹¹ìœ¼ë¡œ ì¸í•œ ì‚¼íˆ¬ì•• ë³€í™”ë¡œ ìˆ˜ì •ì²´(Lens)ì˜ ìˆ˜ë¶„ì´ ë¹ ì ¸ë‚˜ê°€ ëª¨ì–‘ì´ ë³€í•¨ (êµ´ì ˆë¥  ë³€í™”).\n- **í›„ê¸° ì¦ìƒ:** ì¿ ìŠ¤ë§ˆìš¸ í˜¸í¡(Kussmaul respirations), ê³¼ì¼ ëƒ„ìƒˆ(Fruity breath), ì˜ì‹ ë³€í™”.\n### ğŸ’¡ Interesting Concept: Stress Hyperglycemia\n- íŠ¸ë¼ìš°ë§ˆë‚˜ ìˆ˜ìˆ  í›„ í™˜ìì˜ í˜ˆë‹¹ ìƒìŠ¹ì€ **ìƒì¡´ ê¸°ì „(Survival mechanism)**ì¼ ìˆ˜ ìˆìŒ.\n- ë¶€ìƒ ì‹œ ë©´ì—­ ì²´ê³„ì™€ ë‡Œì— ì—°ë£Œë¥¼ ê³µê¸‰í•˜ê¸° ìœ„í•´ ì‹ ì²´ê°€ ì˜ë„ì ìœ¼ë¡œ ì¸ìŠë¦° ì €í•­ì„±ì„ ë†’ì—¬ í˜ˆë‹¹ì„ ì˜¬ë¦¼. ì´ëŠ” ì§ˆë³‘ì´ ì•„ë‹ˆë¼ ì ì‘ ë°˜ì‘ì„.\n---\n## ğŸ”¥ Rapid Fire Recap: The \"Must-Knows\"\n1. **Subtypes:** ë‚˜ì´ê°€ ì•„ë‹ˆë¼ **ìƒí™”í•™ì  ì¦ê±°(C-peptide, Antibodies)**ë¡œ êµ¬ë¶„í•˜ë¼.\n2. **Screening:** 35-70ì„¸ ê³¼ì²´ì¤‘ì´ ê¸°ë³¸ì´ì§€ë§Œ, **HIV, ë‚­í¬ì„± ì„¬ìœ ì¦, ì´ì‹ í™˜ì, PCOS**ëŠ” 35ì„¸ ë¯¸ë§Œì´ë¼ë„ ì„ ë³„ ê²€ì‚¬í•˜ë¼.\n3. **PCOS:** ì§„ë‹¨ì„ ìœ„í•´ **OGTT**ë¥¼ ì‚¬ìš©í•˜ë¼ (ê°€ì¥ ë¯¼ê°í•¨).\n4. **Gastroparesis:** ì¸ìŠë¦° ì˜ì¡´ í™˜ìì˜ **ì‹í›„ ì €í˜ˆë‹¹ + ì†Œí™”ê¸° ì¦ìƒ**ì„ ì°¾ì•„ë¼.\n5. **Neuropathy:** MonofilamentëŠ” ê¶¤ì–‘ ìœ„í—˜ì„, Tuning forkëŠ” ì§„ë™ ê°ê°ì„ ë³¸ë‹¤.\n6. **Retinopathy:** 2í˜• ë‹¹ë‡¨ëŠ” ì§„ë‹¨ ì¦‰ì‹œ, 1í˜• ë‹¹ë‡¨ëŠ” 5ë…„ í›„ ê²€ì‚¬í•œë‹¤.\n**Final Thought:** \"Insulin resistance is a fundamental response to injury and stress.\" (ì¸ìŠë¦° ì €í•­ì„±ì€ ì†ìƒê³¼ ìŠ¤íŠ¸ë ˆìŠ¤ì— ëŒ€í•œ ê·¼ë³¸ì ì¸ ë°˜ì‘ì´ë‹¤.)\n---\n# USMLE Step 2 Deep Dive: Diabetes Pharmacology & Acute Management\nì´ ê°•ì˜ëŠ” ë‹¨ìˆœíˆ ë‹¹ë‡¨ë³‘ì˜ ì •ì˜ë¥¼ ë„˜ì–´ì„œ, **USMLE Step 2**ë¥¼ ëª©ì „ì— ë‘” í•™ìŠµìë¥¼ ìœ„í•´ **\"How(ì–´ë–»ê²Œ ê´€ë¦¬í•  ê²ƒì¸ê°€)\"**ì— ì§‘ì¤‘í•©ë‹ˆë‹¤. ê¸‰ì„± ìœ„ê¸° ê´€ë¦¬(DKA/HHS)ë¶€í„° ë³µì¡í•œ ì•½ë¦¬í•™, ê·¸ë¦¬ê³  í•©ë³‘ì¦ ê´€ë¦¬ê¹Œì§€ ë‹¤ë£¹ë‹ˆë‹¤.\n## 1. The Acute Crisis: DKA vs. HHS ğŸš¨\nì‘ê¸‰ì‹¤(ER) ì„¸íŒ…ì—ì„œ ê°€ì¥ ë¨¼ì € ë§ˆì£¼í•˜ê²Œ ë˜ëŠ” ë‘ ê°€ì§€ ì¹˜ëª…ì ì¸ ê¸‰ì„± í•©ë³‘ì¦ì…ë‹ˆë‹¤. ë³‘íƒœìƒë¦¬ë¥¼ ì´í•´í•˜ë©´ ì¹˜ë£Œ í”„ë¡œí† ì½œì´ ì§ê´€ì ìœ¼ë¡œ ì´í•´ë©ë‹ˆë‹¤.","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-81","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"### A. Diabetic Ketoacidosis (DKA) - Type 1 ìœ„ì£¼\n- **Pathophysiology (The Triad):**\n    1. **Hyperglycemia (ê³ í˜ˆë‹¹)**\n    2. **Ketosis (ì¼€í†¤ì¦):** ì¸ìŠë¦° ê²°í• â†’ ì„¸í¬ê°€ ë‹¹ì„ ëª» ì”€ â†’ ì§€ë°© ë¶„í•´(Lipolysis) â†’ ìœ ë¦¬ì§€ë°©ì‚°(Free Fatty Acids) ê°„ìœ¼ë¡œ ì´ë™ â†’ ì¼€í†¤ì²´(Ketone bodies) ìƒì„±.\n        - ì£¼ìš” ì¼€í†¤: Acetoacetate, **Beta-hydroxybutyrate (â˜… Acidosisì˜ ì£¼ë²”)**.\n    3. **Acidosis (ì‚°ì¦):** ì¼€í†¤ ì¶•ì  â†’ H+ ì´ì˜¨ ë°©ì¶œ â†’ Bicarbonateê°€ ë²„í¼ë§í•˜ë ¤ë‹¤ ê³ ê°ˆë¨ â†’ **Anion Gap Metabolic Acidosis**.\n- **Clinical Presentation:** ë‹¤ë‡¨(Polyuria), ë‹¤ìŒ(Polydipsia), ë³µí†µ(Abdominal pain), blurry vision â˜… , êµ¬ì—­/êµ¬í† (N/V), **Kussmaul respirations** (CO2ë¥¼ ë‚ ë ¤ ë³´ë‚´ë ¤ëŠ” ê¹Šê³  ë¹ ë¥¸ í˜¸í¡), **Fruity odor** (Acetone ëƒ„ìƒˆ).\n### B. Hyperosmolar Hyperglycemic State (HHS) - Type 2 ìœ„ì£¼\n- **íŠ¹ì§•:** ì•½ê°„ì˜ ì¸ìŠë¦°ì€ ë‚¨ì•„ìˆì–´ì„œ Ketogenesis(ì¼€í†¤ ìƒì„±)ëŠ” ì–µì œí•¨. ë”°ë¼ì„œ Acidosisë‚˜ Anion Gapì€ ì—†ìŒ.\n- **ë¬¸ì œì :** í˜ˆë‹¹ì´ **800~1000 mg/dL** ì´ìƒìœ¼ë¡œ ì¹˜ì†ŸìŒ â†’ ì—„ì²­ë‚œ ê³ ì‚¼íˆ¬ì••(Hyperosmolarity) â†’ ì‹¬ê°í•œ íƒˆìˆ˜.\n- **ì¦ìƒ:** **Neurologic signs** (Confusion, Lethargy, Coma)ê°€ í›¨ì”¬ ëšœë ·í•¨.\n---\n## 2. Management Protocol: The \"How-To\" ğŸ¥\nDKAì™€ HHS ì¹˜ë£Œì˜ í•µì‹¬ì€ ìˆœì„œì…ë‹ˆë‹¤. **Fluid â†’ Potassium â†’ Insulin** ìˆœì„œë¥¼ ê¸°ì–µí•˜ì„¸ìš”.\n### Step 1: Fluids (ìˆ˜ë¶„ ê³µê¸‰) ğŸ’§\n- í™˜ìëŠ” ì—„ì²­ë‚œ íƒˆìˆ˜ ìƒíƒœ(Osmotic diuresisë¡œ ì¸í•´ 5~10L ë¶€ì¡±).\n- **ì²« ì¡°ì¹˜:** **Isotonic Saline (Normal Saline)** Bolus (1~2L in first 1-2 hrs)ë¡œ í˜ˆê´€ ë‚´ ë³¼ë¥¨(Intravascular volume) íšŒë³µ.\n### Step 2: The Potassium Trap (â˜… High Yield) ğŸŒ\n- ê°€ì¥ ì¤‘ìš”í•œ ë³´ë“œ ë¬¸ì œ í¬ì¸íŠ¸ì…ë‹ˆë‹¤. ì´ˆê¸° ë© ê²°ê³¼ì—ì„œ í¬íƒ€ìŠ˜(K+)ì´ ì •ìƒì´ê±°ë‚˜ ë†’ì•„ ë³´ì—¬ë„ **ì ˆëŒ€ë¡œ ì†ì§€ ë§ˆì„¸ìš”(Total body depletion ìƒíƒœ)**.\n- Acidosisë¡œ ì¸í•´ ì„¸í¬ ë‚´ì˜ K+ê°€ í˜ˆì•¡ìœ¼ë¡œ ë¹ ì ¸ë‚˜ì˜¨ ìƒíƒœì…ë‹ˆë‹¤. ì¸ìŠë¦°ì„ ì£¼ë©´ K+ê°€ ë‹¤ì‹œ ì„¸í¬ ì•ˆìœ¼ë¡œ ê¸‰ê²©íˆ ë“¤ì–´ê°€ **Fatal Arrhythmia**ë¥¼ ìœ ë°œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n- ì‹¤ì œë¡œëŠ” hypokalemiaì¸ë° ê²€ì‚¬ìƒ ë†’ì•„ë³´ì´ëŠ” ì°©ê°ì¸ê²ƒ.\n- **Algorithm (Rule of 3.3):**\n    - **K+ < 3.3:** **Insulin ê¸ˆì§€!** K+ë¥¼ ë¨¼ì € ë³´ì¶©.\n    - **K+ 3.3 ~ 5.2:** K+ë¥¼ ë³´ì¶©í•˜ë©´ì„œ Insulin ì‹œì‘.\n    - **K+ > 5.2:** Insulin ì‹œì‘ (K+ ëª¨ë‹ˆí„°ë§).\n### Step 3: Insulin ğŸ’‰\n- **IV Regular Insulin** (0.1 units/kg/hr) ì‚¬ìš©.\n- **ëª©í‘œ:** í˜ˆë‹¹ì„ ì‹œê°„ë‹¹ 50~75 mg/dLì”© ì²œì²œíˆ ë‚®ì¶¤. ë„ˆë¬´ ë¹¨ë¦¬ ë‚®ì¶”ë©´ **Cerebral Edema (ë‡Œë¶€ì¢…)** ìœ„í—˜!\n- **Closing the Gap:** í˜ˆë‹¹ì´ 200~250 mg/dLê¹Œì§€ ë–¨ì–´ì ¸ë„ Anion Gapì´ ë‹«íˆì§€ ì•Šì•˜ë‹¤ë©´(Acidosis í•´ê²° ì•ˆ ë¨), ì¸ìŠë¦°ì„ ë„ì§€ ë§ê³  **IV fluidsì— Dextrose(D5W)ë¥¼ ì¶”ê°€**í•´ì„œ ì¸ìŠë¦°ì„ ê³„ì† ì£¼ì…í•´ì•¼ í•¨ (Sugarë¥¼ ë¨¹ì—¬ê°€ë©° ì¸ìŠë¦°ì„ ì¤Œ).\n### Step 4: Transition\n- Gapì´ ë‹«íˆê³  í™˜ìê°€ ì‹ì‚¬ ê°€ëŠ¥í•˜ë©´ í”¼í•˜(SubQ) ì¸ìŠë¦°ìœ¼ë¡œ ì „í™˜.\n- **Overlap bridge:** IV ë„ê¸° 1~2ì‹œê°„ ì „ì— SubQ(Long-acting)ë¥¼ ì¤˜ì„œ ì¸ìŠë¦° ê³µë°±ì„ ë§‰ì•„ì•¼ í•¨(Rebound DKA ë°©ì§€).\n---\n## 3. Pharmacology: The Drug Classes ğŸ’Š\nì•½ë¬¼ ê¸°ì „, ë¶€ì‘ìš©, ê¸ˆê¸° ì‚¬í•­ì„ ì™„ë²½íˆ ë§¤ì¹­í•´ì•¼ í•©ë‹ˆë‹¤.\n| **ì•½ë¬¼ ê³„ì—´** | **ê¸°ì „ ë° íŠ¹ì§•** | **â˜… Key Side Effects / Notes** |\n| --- | --- | --- |\n| **Biguanides**\n(Metformin) | **1st Line.** ê°„ì˜ í¬ë„ë‹¹ ìƒì„±(Gluconeogenesis) ì–µì œ. ì¸ìŠë¦° ê°ìˆ˜ì„± ê°œì„ . | â€¢ **Lactic Acidosis:** ì‹ ì¥/ê°„ ê¸°ëŠ¥ ì €í•˜ ì‹œ ìœ„í—˜.\nâ€¢ **eGFR < 30:** ê¸ˆê¸° (Contraindication).\nâ€¢ GI Upset (ì„¤ì‚¬ ë“±), B12 ê²°í•.\nâ€¢ **Weight Neutral** (ì•½ê°„ì˜ ê°ì†Œ). |\n| **Sulfonylureas**\n(Glipizide, Glimepiride, Glyburide) (ëˆì—†ìœ¼ë©´) | ì·Œì¥ ë² íƒ€ì„¸í¬ ìê·¹ (K+ ì±„ë„ ì°¨ë‹¨ â†’ Ca ìœ ì… â†’ ì¸ìŠë¦° ë¶„ë¹„). \"Squeeze the pancreas.\" | â€¢ **Hypoglycemia** (ê°€ì¥ í° ìœ„í—˜).\nâ€¢ **Weight Gain**.\nâ€¢ **Glyburide:** ì‹ ë¶€ì „ í™˜ì ê¸ˆê¸° (í™œì„± ëŒ€ì‚¬ì²´ ì¶•ì ). |\n| **TZDs**\n(Pioglitazone) | **PPAR-gamma agonist** (í•µ ìˆ˜ìš©ì²´). ì¸ìŠë¦° ë¯¼ê°ë„ ì¦ê°€. | â€¢ **Fluid Retention/Edema:** **CHF Class 3/4 í™˜ì ì ˆëŒ€ ê¸ˆê¸°!**\nâ€¢ ê³¨ì ˆ ìœ„í—˜ ì¦ê°€, ì²´ì¤‘ ì¦ê°€.\nâ€¢ ë°©ê´‘ì•” ì´ìŠˆ(ê³¼ê±°). |\n| **GLP-1 Agonists**\n(-tides: Exenatide, Liraglutide, Semaglutide) | \"The Darlings.\" í¬ë„ë‹¹ ì˜ì¡´ì„± ì¸ìŠë¦° ë¶„ë¹„â†‘, ê¸€ë£¨ì¹´ê³¤â†“, ìœ„ ë°°ì¶œ ì§€ì—°. | â€¢ **Weight Loss** (Satiety ì¦ê°€).\nâ€¢ **CV Benefit** (ì‹¬í˜ˆê´€ ë³´í˜¸).\nâ€¢ GI ë¶€ì‘ìš©(N/V) í”í•¨.\nâ€¢ **Contraindication:** Medullary Thyroid Cancer (MEN 2) ê³¼ê±°ë ¥/ê°€ì¡±ë ¥. |\n| **DPP-4 Inhibitors**\n(-gliptins: Sitagliptin, Linagliptin) | GLP-1 ë¶„í•´ íš¨ì†Œ ì–µì œ. GLP-1 íš¨ê³¼ ì—°ì¥. | â€¢ Weight Neutral, ì˜ ê²¬ë”¤(Gentle).\nâ€¢ Pancreatitis ìœ„í—˜ì„±(ì•½í•¨).\nâ€¢ ì‹¬ë¶€ì „ ìœ„í—˜ ì‹ í˜¸(Saxagliptin). |\n| **SGLT2 Inhibitors**\n(-flozins: Empagliflozin, Dapagliflozin) | ì‹ ì¥(PCT)ì—ì„œ í¬ë„ë‹¹ ì¬í¡ìˆ˜ ì°¨ë‹¨ â†’ ì†Œë³€ìœ¼ë¡œ ë‹¹ ë°°ì¶œ. | â€¢ **Weight Loss**, í˜ˆì•• ê°ì†Œ.\nâ€¢ **Renal & Cardiac Protective** (CKD, HF í™˜ìì— ê°•ë ¥ ì¶”ì²œ).\nâ€¢ **UTI, Yeast Infection** (ê³°íŒ¡ì´ ê°ì—¼).\nâ€¢ â˜… **Euglycemic DKA:** í˜ˆë‹¹ì´ ì •ìƒì´ì§€ë§Œ DKA ë°œìƒ ê°€ëŠ¥. |\n---","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-101","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"## 4. Insulin Types & Strategy ğŸ’‰\n### **Types**\n- **Basal (Long-acting):** Glargine, Degludec. \"Peakless\" (í”¼í¬ ì—†ì´ 24ì‹œê°„ ì§€ì†). ë°°ê²½ ì¸ìŠë¦° ìš”êµ¬ëŸ‰ ì»¤ë²„.\n- **Bolus (Rapid-acting):** Lispro, Aspart, Glulisine. ì‹ì‚¬ ì§ì „ íˆ¬ì—¬. 15ë¶„ ë‚´ ì‘ìš© ì‹œì‘.\n- Intermediate (NPH): peakìˆìŒ. ì˜ ì•ˆì”€. hypoglycemiaìœ„í—˜.\n- RI: ì˜ ì•ˆì”€. DKA, HHS ë•Œ ì”€. Inpatient IV drip ë•ŒëŠ” ì”€.\n### **Management Strategy**\n- **Inpatient (ì…ì› í™˜ì):** ê²½êµ¬ì•½(Oral meds)ì€ ëŠìŠµë‹ˆë‹¤.\n    - **Basal-Bolus ìš”ë²•**ì´ Sliding Scale ë‹¨ë… ìš”ë²•ë³´ë‹¤ í›¨ì”¬ ìš°ì›”í•©ë‹ˆë‹¤.\n    - **Correction Scale:** ì‹ì „ í˜ˆë‹¹ì— ë”°ë¼ ì¶”ê°€ë¡œ ì£¼ëŠ” ì¸ìŠë¦°.\n---\n## 5. T2DM Outpatient Management Algorithm (ì™¸ë˜ ì¹˜ë£Œ ì•Œê³ ë¦¬ì¦˜) ğŸš€\në‹¨ìˆœíˆ ì•½ë¬¼ ì¢…ë¥˜ë¥¼ ì•„ëŠ” ê²ƒë³´ë‹¤ **\"ì–´ë–¤ í™˜ìì—ê²Œ ë¬´ì—‡ì„ ë¨¼ì € ì“¸ ê²ƒì¸ê°€?\"**ë¥¼ ê²°ì •í•˜ëŠ” ê²ƒì´ ì‹œí—˜ì˜ í•µì‹¬ì…ë‹ˆë‹¤.\n- ê°œì¸í™”ëœ hba1c ëª©í‘œ\n    - ì¼ë°˜ì ìœ¼ë¡œ 7%\n    - ê±´ê°•í•˜ê³  ì Šì€ í™˜ì 6.5%\n    - comorbididities, ë…¸ì¸ 8%\n### 1.1  Step 1: The Anchor (1ë‹¨ê³„: ì‹œì‘ì€ ë©”íŠ¸í¬ë¥´ë¯¼)\n- **Standard of Care:** ì§„ë‹¨ ì¦‰ì‹œ ìƒí™œìŠµê´€ êµì •(Lifestyle)ê³¼ í•¨ê»˜ **Metformin**ì„ ì‹œì‘í•©ë‹ˆë‹¤.\n- **ì˜ˆì™¸ (Exceptions):**\n    - eGFR < 30 (CKD stage 4, 5).\n    - Acidosis risk (ì‹¬í•œ ê°„ë¶€ì „ ë“±).\n### 1.2. Step 2: Escalation Strategy (2ë‹¨ê³„: ì•½ë¬¼ ì¶”ê°€) ğŸ“ˆ\n3ê°œì›” ë’¤ A1cê°€ ëª©í‘œ(ì£¼ë¡œ < 7%)ì— ë„ë‹¬í•˜ì§€ ëª»í–ˆë‹¤ë©´, **ë‘ ë²ˆì§¸ ì•½ì œ**ë¥¼ ì¶”ê°€í•©ë‹ˆë‹¤. ì´ë•Œ ì„ íƒ ê¸°ì¤€ì€ **ë™ë°˜ ì§ˆí™˜(Comorbidities)**ì…ë‹ˆë‹¤.\n| **í™˜ìì˜ ë™ë°˜ ì§ˆí™˜ (Comorbidity)** | **ì¶”ì²œ ì•½ë¬¼ (Drug of Choice)** | **ì´ìœ  (Rationale)** |\n| --- | --- | --- |\n| **Heart Failure (ì‹¬ë¶€ì „)** ğŸ«€ | **SGLT-2 Inhibitor** (Empagliflozin ë“±) | ì‹¬ë¶€ì „ ì…ì› ë° ì‚¬ë§ë¥  ê°ì†Œ ì…ì¦. |\n| **CKD (ë§Œì„± ì‹ ë¶€ì „)** ì½©íŒ¥ | **SGLT-2 Inhibitor** | ì‹ ì¥ ê¸°ëŠ¥ ì•…í™” ì§€ì—° (Nephroprotection). |\n| **ASCVD (ì£½ìƒê²½í™” ì‹¬í˜ˆê´€ì§ˆí™˜)** ğŸ©¸\n(MI, Stroke, CAD ë³‘ë ¥) | **GLP-1 Agonist** or **SGLT-2 Inhibitor** | ì£¼ìš” ì‹¬í˜ˆê´€ ì‚¬ê±´(MACE) ì˜ˆë°© íš¨ê³¼. |\n| **Obesity (ë¹„ë§Œ)** âš–ï¸ | **GLP-1 Agonist** (Semaglutide ë“±) | ê°•ë ¥í•œ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼. |\n| **Cost Issues (ë¹„ìš© ë¬¸ì œ)** ğŸ’¸ | **Sulfonylurea** or **TZD** | ì•½ê°’ì´ ë§¤ìš° ì €ë ´í•¨ (ë‹¨, ì €í˜ˆë‹¹/ì²´ì¤‘ì¦ê°€ ìœ„í—˜ ê°ìˆ˜). |\n### 1.3. â˜… The \"Insulin First\" Rule (ì–¸ì œ ë°”ë¡œ ì¸ìŠë¦°ì„ ì“°ëŠ”ê°€?) ğŸš¨\nê²½êµ¬ ì•½ë¬¼ì„ ê±´ë„ˆë›°ê³  **ì§„ë‹¨ ì¦‰ì‹œ ì¸ìŠë¦°**ì„ ì¨ì•¼ í•˜ëŠ” ê²½ìš°ì…ë‹ˆë‹¤.\n- **ê¸°ì¤€ (Criteria):**\n    1. **ì²˜ìŒì— HbA1c > 10%**\n    2. **Random Glucose > 300 mg/dL**\n    3. **Severe Symptoms (Catabolic State):** ë‹¤ìŒ(Polydipsia), ë‹¤ë‡¨(Polyuria), **ì²´ì¤‘ ê°ì†Œ(Weight loss)**.\n- **ì´ìœ :** í¬ë„ë‹¹ ë…ì„±(Glucotoxicity)ì´ ë„ˆë¬´ ì‹¬í•´ ê²½êµ¬ ì•½ë¬¼ì´ ë“£ì§€ ì•Šê±°ë‚˜, ì·Œì¥ ë² íƒ€ì„¸í¬ê°€ ê±°ì˜ ê³ ê°ˆëœ ìƒíƒœ(Catabolic)ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¼ë‹¨ ì¸ìŠë¦°ìœ¼ë¡œ ë¶ˆì„ ëˆ ë’¤(Break toxicity), ë‚˜ì¤‘ì— ê²½êµ¬ì•½ìœ¼ë¡œ ì „í™˜(De-escalate)ì„ ê³ ë ¤í•©ë‹ˆë‹¤.\n- ê²½êµ¬ì•½ìœ¼ë¡œ ë¶ˆì¶©ë¶„í•˜ì—¬ ë³´ì¶©í•˜ëŠ” ê²½ìš°\n    - Basal ì¶”ê°€ë¶€í„° ì‹œì‘í•œë‹¤.\n---\n## 6. Diabetic Nephropathy","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-121","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"### 1. Pathophysiology: The Pressure Cooker (ê¸°ì „)\nê°•ì‚¬ëŠ” ì‹ ì¥ ì†ìƒì˜ ì‹œì‘ì„ **'ì••ë ¥ì†¥(Pressure Cooker)'**ì— ë¹„ìœ í•˜ì—¬ ì„¤ëª…í•©ë‹ˆë‹¤.\n- **Hyperfiltration (ê³¼ì—¬ê³¼):**\n    - ì´ˆê¸° ë‹¨ê³„ì—ì„œ ê³ í˜ˆë‹¹ì€ ì‹ ì¥ìœ¼ë¡œ ê°€ëŠ” í˜ˆë¥˜ë¥¼ ì¦ê°€ì‹œí‚µë‹ˆë‹¤.\n    - ì´ë¡œ ì¸í•´ ì‚¬êµ¬ì²´(Glomerulus) ë‚´ë¶€ì˜ ì••ë ¥ì´ ë†’ì•„ì§€ê³ , ì‹ ì¥ì€ í‰ì†Œë³´ë‹¤ ë” ë§ì€ ì¼ì„ í•˜ê²Œ ë©ë‹ˆë‹¤(Hyperfiltration).\n- **Damage (ì†ìƒ):**\n    - ë†’ì€ ì••ë ¥ì´ ì§€ì†ë˜ë©´ ì‚¬êµ¬ì²´ ê¸°ì €ë§‰ì´ ì†ìƒë˜ê³ , ê²°êµ­ êµ¬ë©ì´ ì»¤ì ¸ì„œ ë‹¨ë°±ì§ˆ(ì•Œë¶€ë¯¼)ì´ ì†Œë³€ìœ¼ë¡œ ìƒˆì–´ ë‚˜ì˜¤ê²Œ ë©ë‹ˆë‹¤.\n    - ì´ê²ƒì´ ë°”ë¡œ **Microalbuminuria (ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨)**ì…ë‹ˆë‹¤.\n### 2. Screening: Catching it Early (ì„ ë³„ ê²€ì‚¬) ğŸ•µï¸â€â™‚ï¸\nê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ì‹ ì¥ ê¸°ëŠ¥(Cr)ì´ ë–¨ì–´ì§€ê¸° **ì „**ì—, ë¯¸ì„¸í•œ ì†ìƒ ì§•í›„ë¥¼ ì°¾ì•„ë‚´ëŠ” ê²ƒì…ë‹ˆë‹¤.\n- **The Test:** **Spot Urine Albumin/Creatinine Ratio (UACR)**\n    - â˜… **Dipstick is Useless:** ì¼ë°˜ ì†Œë³€ê²€ì‚¬ ìŠ¤í‹±(Dipstick)ì€ 'ë¯¸ì„¸' ì•Œë¶€ë¯¼ë‡¨ë¥¼ ì¡ì•„ë‚´ì§€ ëª»í•©ë‹ˆë‹¤. ë°˜ë“œì‹œ **UACR** ì •ëŸ‰ ê²€ì‚¬ë¥¼ í•´ì•¼ í•©ë‹ˆë‹¤.\n- **The Cutoff:**\n    - **Normal:** < 30 mg/g\n    - **Microalbuminuria (Moderately increased):** **30 - 300 mg/g**\n    - **Macroalbuminuria (Severely increased):** > 300 mg/g\n    - **ì§„ë‹¨ ê¸°ì¤€:** UACRì´ **30 mg/g ì´ìƒ**ì´ë©´ ë‹¹ë‡¨ë³‘ì„± ì‹ ì¦ì˜ ì´ˆê¸° ì§•í›„ë¡œ ê°„ì£¼í•©ë‹ˆë‹¤.\n- **When to Screen (ê²€ì‚¬ ì‹œê¸°):**\n    - **Type 2 DM:** **ì§„ë‹¨ ì¦‰ì‹œ (At diagnosis)** ì‹œì‘í•˜ì—¬ ë§¤ë…„ ê²€ì‚¬. (ì œ2í˜•ì€ ì§„ë‹¨ ì‹œì ì— ì´ë¯¸ ì•“ì€ ì§€ ì˜¤ë˜ë˜ì—ˆì„ ìˆ˜ ìˆê¸° ë•Œë¬¸).\n    - **Type 1 DM:** **ì§„ë‹¨ 5ë…„ í›„**ë¶€í„° ì‹œì‘. (ê¸‰ì„± ë°œë³‘ì´ë¯€ë¡œ ì´ˆê¸° 5ë…„ì€ ì‹ ì¥ í•©ë³‘ì¦ì´ ë“œë¬¾).\n### 3. Treatment: Turning Down the Pressure (ì¹˜ë£Œ) ğŸ’Š\nì¹˜ë£Œì˜ í•µì‹¬ì€ ì‚¬êµ¬ì²´ ë‚´ë¶€ì˜ ì••ë ¥ì„ ë‚®ì¶°ì„œ ì½©íŒ¥ì„ ë³´í˜¸í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.\n### 3.1. ACE Inhibitors & ARBs (The Gold Standard) ğŸ†\n- **ì•½ë¬¼:** Lisinopril, Losartan ë“±.\n- **Indication (ì ì‘ì¦):**\n    - **ê³ í˜ˆì••ì´ ì—†ë”ë¼ë„(Normotensive)**, **ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨(Microalbuminuria)ê°€ ê²€ì¶œë˜ë©´ ë¬´ì¡°ê±´ ì‹œì‘**í•©ë‹ˆë‹¤.\n    - ì´ëŠ” í˜ˆì•• ì¡°ì ˆ ëª©ì ì´ ì•„ë‹ˆë¼ ì‹ ì¥ ë³´í˜¸ ëª©ì ì…ë‹ˆë‹¤.\n- **Mechanism (ê¸°ì „):**\n    - **Efferent Arteriole Dilation (ìˆ˜ì¶œ ì†Œë™ë§¥ í™•ì¥):** ë‚˜ê°€ëŠ” í˜ˆê´€ì„ ë„“í˜€ì£¼ì–´ ì‚¬êµ¬ì²´ ë‚´ë¶€ì˜ ì••ë ¥ì„ ë–¨ì–´ëœ¨ë¦½ë‹ˆë‹¤. (ë§ˆì¹˜ ëŒì˜ ìˆ˜ë¬¸ì„ ì—´ì–´ ìˆ˜ìœ„ë¥¼ ë‚®ì¶”ëŠ” ì›ë¦¬).\n### 3.2. í˜ˆë‹¹ ì¡°ì ˆ SGLT-2 Inhibitors (The New Champion) ğŸŒŸ\n- **ì•½ë¬¼:** Empagliflozin, Dapagliflozin ë“±.\n- **Role:** ìµœê·¼ ê°€ì´ë“œë¼ì¸ì—ì„œ **CKD ì§„í–‰ì„ ëŠ¦ì¶”ëŠ” íš¨ê³¼**ê°€ ì…ì¦ë˜ì–´, ACEi/ARBì™€ í•¨ê»˜ ì‹ ì¥ ë³´í˜¸ì˜ í•µì‹¬ ì¶•ìœ¼ë¡œ ë¶€ìƒí–ˆìŠµë‹ˆë‹¤.\n    - íŠ¹íˆ eGFRì´ ë–¨ì–´ì ¸ ìˆëŠ” í™˜ìì—ê²Œë„ ì‹ ì¥ ë³´í˜¸ íš¨ê³¼(Renoprotective)ê°€ ê°•ë ¥í•©ë‹ˆë‹¤.\n---\n## ğŸ’¡ Clinical Pearl (ì‹œí—˜ì— ë‚˜ì˜¤ëŠ” í¬ì¸íŠ¸)\n- **Scenario:** í˜ˆì•• 120/80ì¸ ë‹¹ë‡¨ í™˜ìì˜ ì†Œë³€ ê²€ì‚¬ì—ì„œ UACRì´ 45 mg/gì´ ë‚˜ì™”ë‹¤. ì¡°ì¹˜ëŠ”?\n    - **ì •ë‹µ:** **Lisinopril (ACEi) ì‹œì‘.** (í˜ˆì••ì´ ì •ìƒì´ë¼ë„ ë‹¨ë°±ë‡¨ê°€ ìˆìœ¼ë©´ ì”ë‹ˆë‹¤.)\n- **Contraindication:** ë§Œì•½ í™˜ìê°€ ì„ì‹  ê³„íšì´ ìˆê±°ë‚˜ ì„ì‹  ì¤‘ì´ë¼ë©´?\n    - ACEi/ARBëŠ” ê¸ˆê¸°ì…ë‹ˆë‹¤.\n---\n## 7. Metabolic syndrome\n- 5ê°€ì§€ì¤‘ 3ê°€ì§€ì´ìƒ\n1. **Abdominal Obesity (ë³µë¶€ ë¹„ë§Œ):**\n    - ê°€ì¥ ì¤‘ìš”í•œ ì§€í‘œì…ë‹ˆë‹¤. ë‚´ì¥ ì§€ë°©(Visceral fat)ì´ ì¸ìŠë¦° ì €í•­ì„±ì˜ í•µì‹¬ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.\n    - â™‚ï¸ **Men:** > 40 inches\n    - â™€ï¸ **Women:** > 35 inches\n2. **Hypertriglyceridemia (ê³ ì¤‘ì„±ì§€ë°©):**\n    - **> 150 mg/dL**. (í˜¹ì€ ì•½ë¬¼ ë³µìš© ì¤‘).\n3. **Low HDL (ë‚®ì€ HDL):**\n    - â™‚ï¸ **Men:** < 40 mg/dL\n    - â™€ï¸ **Women:** < 50 mg/dL\n4. **Hypertension (ê³ í˜ˆì••):**\n    - **> 130 / 85 mmHg**. (ì¼ë°˜ì ì¸ ê³ í˜ˆì•• ì§„ë‹¨ ê¸°ì¤€ì¸ 130/80ê³¼ ë¯¸ì„¸í•˜ê²Œ ë‹¤ë¥´ë‹ˆ ì£¼ì˜! ìˆ˜ì¶•ê¸° 130, ì´ì™„ê¸° 85).\n5. **Hyperglycemia (ê³ í˜ˆë‹¹):**\n    - **Fasting Glucose > 100 mg/dL**. (ë‹¹ë‡¨ë³‘ ì§„ë‹¨ ê¸°ì¤€ì¸ 126ë³´ë‹¤ ë‚®ìŠµë‹ˆë‹¤. ì¦‰, **Pre-diabetes** ë‹¨ê³„ë¶€í„° í¬í•¨ë©ë‹ˆë‹¤).\n- Why do we care? (ì„ìƒì  ì˜ì˜) ğŸš‘\n    - d/t insulin resistance\n    - **Cardiovascular Risk:** ì‹¬í˜ˆê´€ ì§ˆí™˜ ë°œìƒ ìœ„í—˜ì´ 2ë°° ì´ìƒ ì¦ê°€í•©ë‹ˆë‹¤.\n    - **Type 2 Diabetes:** ë‹¹ë‡¨ë³‘ ë°œìƒ ìœ„í—˜ì´ 5ë°° ì´ìƒ ì¦ê°€í•©ë‹ˆë‹¤.\n    - **NASH (Non-alcoholic Steatohepatitis):** ë¹„ì•Œì½”ì˜¬ì„± ì§€ë°©ê°„ì—¼ê³¼ ë§¤ìš° ê°•ë ¥í•˜ê²Œ ì—°ê´€ë˜ì–´ ìˆìŠµë‹ˆë‹¤. (ALT > AST íŒ¨í„´).\n## 8. Hypoglycemia (ì €í˜ˆë‹¹) ğŸ“‰\n### 1. Definition & Whipple's Triad","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-141","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"- í˜ˆë‹¹ **< 70 mg/dL**.\n- **Whipple's Triad:**\n    1. ì €í˜ˆë‹¹ ì¦ìƒ (Sweating, tremor, confusion).\n    2. ì‹¤ì œ ë‚®ì€ í˜ˆë‹¹ ìˆ˜ì¹˜.\n    3. í¬ë„ë‹¹ íˆ¬ì—¬ í›„ ì¦ìƒ í˜¸ì „.\n- symptoms\n    - adrenergic : epinephrine, norepinephrine ì¦ê°€. ë¶ˆì•ˆ, ê¸´ì¥, ë•€\n    - neuroglycopenic: ë‡Œê°€ ë‹¹ì´ ì—†ì–´ì„œ ë‚˜íƒ€ë‚˜ëŠ” ì¦ìƒ.\n### 2. Treatment\n- **Awake:** ì£¼ìŠ¤ë‚˜ ì‚¬íƒ• ë“± ë¹ ë¥¸ íƒ„ìˆ˜í™”ë¬¼ ì„­ì·¨ (\"Rule of 15\").\n- **Unconscious (IV access O):** **IV Dextrose (D50)**. (ê°€ì¥ í™•ì‹¤í•¨).\n- **Unconscious (IV access X):** **IM Glucagon** (ê·¼ìœ¡ ì£¼ì‚¬).\n### 3. â˜… Diagnostic Workup (The Detective Work) ğŸ•µï¸â€â™‚ï¸\në‹¹ë‡¨ê°€ ì—†ëŠ” í™˜ìê°€ ì €í˜ˆë‹¹ìœ¼ë¡œ ì™”ì„ ë•Œ, ì›ì¸(ì¸ìŠë¦°ì¢… vs ì™¸ë¶€ ì£¼ì… vs ì•½ë¬¼)ì„ ê°ë³„í•˜ëŠ” ì•Œê³ ë¦¬ì¦˜ì…ë‹ˆë‹¤.\n| **Condition** | **Insulin** | **C-Peptide â˜…** | **Pro-insulin** | **Sulfonylurea Screen** |\n| --- | --- | --- | --- | --- |\n| **Exogenous Insulin** (ì£¼ì‚¬ íˆ¬ì—¬) | â¬†ï¸ High | **â¬‡ï¸ Low** | â¬‡ï¸ Low | (-) |\n| **Insulinoma** (ì¢…ì–‘) | â¬†ï¸ High | **â¬†ï¸ High** | â¬†ï¸ High | (-) |\n| **Sulfonylurea Abuse** (ì•½ë¬¼ ë³µìš©) | â¬†ï¸ High | **â¬†ï¸ High** | Normal | **(+) Positive** |\n## âš¡ Rapid Fire Recap (Must-Know Summary)\nì˜¤ë””ì˜¤ ë§ˆì§€ë§‰ì— ì •ë¦¬ëœ, **Step 2 ì‹œí—˜ì¥ì— ë“¤ì–´ê°€ê¸° ì „ ë°˜ë“œì‹œ ê¸°ì–µí•´ì•¼ í•  ë‚´ìš©**ì…ë‹ˆë‹¤.\n1. **DKA/HHS 1ìˆœìœ„ ì¹˜ë£Œ:** **Fluids (ìˆ˜ì•¡)**ì´ ë¨¼ì €ë‹¤! (1-2L Normal Saline).\n2. **Insulin ì „ K+ í™•ì¸:** K < 3.3ì´ë©´ **ì¸ìŠë¦° ì£¼ì§€ ë§ˆë¼(Hold)**. í™˜ì ì£½ëŠ”ë‹¤. 3.3 ë„˜ìœ¼ë©´ ì£¼ë©´ì„œ ì¸ìŠë¦° ì¤€ë‹¤. 5.2 ë„˜ìœ¼ë©´ ì¤€ë‹¤.\n3. **Metformin:** ì‹ ì¥ ê¸°ëŠ¥ í™•ì¸ (**GFR < 30 ê¸ˆê¸°**, Lactic Acidosis ìœ„í—˜).\n4. **Sulfonylureas:** ì €í˜ˆë‹¹ê³¼ ì²´ì¤‘ ì¦ê°€ì˜ ì£¼ë²”.\n5. **TZDs:** ì‹¬ë¶€ì „(CHF) í™˜ìì—ê²Œ **ê¸ˆê¸°**. (ë¶€ì¢… ìœ ë°œ).\n6. **SGLT-2 Inhibitors:** ì†Œë³€ìœ¼ë¡œ ë‹¹ ë°°ì¶œ. **UTI/Yeast infection** ì£¼ì˜. **Euglycemic DKA** ê°€ëŠ¥ì„± ì—¼ë‘.\n7. ì‹¬í˜ˆê´€ê³„, ì½©íŒ¥, ì‹¬ë¶€ì „ ìˆìœ¼ë©´ metformin ë‹¤ìŒë‹¨ê³„ë¡œ SGLT-2 inh.\n8. **Microalbuminuria:** 30~300 êµ¬ê°„ì—ì„œ ë°œê²¬ë˜ë©´ **ACEi/ARB** ì‹œì‘. (Efferent arteriole í™•ì¥).\n9. **Hypoglycemia Workup:** C-peptideë¥¼ í™•ì¸í•´ì„œ **Insulinoma(High)**ì™€ **ì™¸ë¶€ ì£¼ì‚¬(Low)**ë¥¼ êµ¬ë³„í•˜ë¼.\n---\n# ğŸ¥ Deep Dive: USMLE Step 2ë¥¼ ìœ„í•œ Adrenal Pathology (ë¶€ì‹  ë³‘ë¦¬í•™)\n## 1. Introduction: Taming the Beast ğŸ¦\n- **Goal:** USMLE Step 2 ë° ì‹¤ì œ ì„ìƒì„ ìœ„í•œ Mental Framework êµ¬ì¶•.\n- **í•µì‹¬ í¬ì¸íŠ¸:** ë‹¨ìˆœ ì•”ê¸°ë¥¼ ë„˜ì–´, **\"Next Best Step\"** (ë‹¤ìŒ ë‹¨ê³„ëŠ” ë¬´ì—‡ì¸ê°€?)ì„ ì´í•´í•˜ëŠ” ê²ƒì´ ëª©í‘œ.\n- **Adrenal Gland (ë¶€ì‹ ):** ì•½ 4gì˜ ì‘ì€ ê¸°ê´€ì´ì§€ë§Œ, Salt, Sugar, Blood Pressure, Stress ë°˜ì‘ì„ ì¡°ì ˆí•˜ëŠ” High-stakes organ.\n- **ê¸°ë³¸ ìƒë¦¬í•™ Mnemonic:**\n    - ğŸ§‚ **Salt** (Mineralocorticoids/Aldosterone)\n    - ğŸ­ **Sugar** (Glucocorticoids/Cortisol)\n    - ğŸ’ **Sex** (Androgens)\n    - ğŸš€ **Speed** (Catecholamines)\n- **ë¶„ë¥˜ (Categories):**\n    1. **Adrenal Excess** (ê³¼ë‹¤) -> Functional masses.\n    2. **Adrenal Masses** (íŠ¹íˆ Pheochromocytoma).\n    3. **Adrenal Insufficiency** (ë¶€ì¡±).\n---\n## 2. Adrenal Excess: The Functional Masses ğŸ“ˆ\n**ì„ìƒ ì–‘ìƒ (Clinical Presentation):** ì „ì‹  ì¦ìƒ(ì¡°ì ˆë˜ì§€ ì•ŠëŠ” HTN, ì²´í˜• ë³€í™” ë“±) ë˜ëŠ” **Incidentaloma**(CT ë“±ì—ì„œ ìš°ì—°íˆ ë°œê²¬ëœ ì¢…ì–‘)ë¡œ ë‚´ì›.\n**Incidentaloma ë°œê²¬ ì‹œ ì „ëµ:**\n- ì¦‰ì‹œ ë‘ ê°€ì§€ ì§ˆë¬¸ì„ ë˜ì ¸ì•¼ í•¨:\n    1. Is it cancer? (ì•”ì¸ê°€?)\n    2. Is it functional? (í˜¸ë¥´ëª¬ì„ ë¶„ë¹„í•˜ëŠ”ê°€?)\n- **The Golden Rule:** â˜… **Biochemistry before Biopsy.** (ìƒê²€ ì „ ìƒí™”í•™ ê²€ì‚¬ í•„ìˆ˜)\n    - *ì£¼ì˜:* ìƒí™”í•™ì  í™•ì¸ ì—†ì´ Pheochromocytomaë¥¼ ìƒê²€(Biopsy)í•˜ë©´, Adrenalineì´ ëŒ€ëŸ‰ ë°©ì¶œë˜ì–´ Hypertensive Crisisë¡œ í™˜ìê°€ ì‚¬ë§í•  ìˆ˜ ìˆìŒ.","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-161","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","mnemonic"]}
